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1	  	  INTRODUCTION	  	  Patients	   receiving	   palliative	   care	   often	   suffer	   from	  pain,	   anxiety	   and	   depression.	  Therefore,	   in	   the	   final	   stage	  of	   their	   life	   they	  may	  need	   sedation	   to	  ease	  anxiety.	  	  Several	   drugs,	   such	   as	   opioids,	   benzodiazepines,	   antidepressants	   or	   particular	  antipsychotics	   are	   used	   to	   ease	   anxiety	   (Devlin	   and	  Roberts	   2011).	  However,	   all	  these	   drugs	   dispose	   dose-­‐related	   adverse	   effects,	   and	   to	   reduce	   these,	   a	  multimodal	  therapy	  is	  often	  used	  to	  decrease	  individual	  drug	  doses	  or	  to	  achieve	  synergistic	   interaction.	   This	   means	   that	   several	   drugs	   affecting	   via	   different	  receptor-­‐systems	   are	   combined.	   Especially	   opioids	   but	   also	   benzodiazepines	   are	  associated	   with	   adverse	   effects	   such	   as	   tolerance,	   nausea,	   constipation	   and	  respiratory	   depression	   (Barr	   et	   al.	   2001:	   Swart	   et	   al.	   2006).	   Hence,	   there	   is	   a	  clinical	  need	  for	  alternative	  drug	  regimens	  to	  treat	  palliative	  care	  patients.	  	  Alpha-­‐2-­‐agonists,	  which	  stimulate	  the	  α2-­‐adrenergic	  receptors	   in	  the	  sympathetic	  nervous	   system,	   have	   gained	   recent	   interest	   due	   to	   their	   sedative,	   analgesic,	  anxiolytic	   and	   sympatholytic	   effects	   (Scheinin	   et	   al.	   1989:	   Hunter	   et	   al.	   1997:	  Buerkle	  and	  Yaksh	  1998:	  Sallinen	  et	  al.	  1998).	  Dexmedetomidine,	  a	  recently	  found	  alpha-­‐2-­‐agonist,	   has	   been	   demonstrated	   to	   induce	   dose-­‐dependent	   sedation	  without	  any	  risk	  of	  ventilatory	  depression	  (Ebert	  et	  al.	  2000:	  Petroz	  et	  al.	  2006).	  Theoretically	   and	   based	   on	   published	   case	   reports	   and	   uncontrolled	   series	  dexmedetomidine	   may	   provide	   benefits	   for	   the	   palliative	   patient,	   as	   it	   induces	  analgesia	  and	  sedation	  with	  no	   risk	  of	   respiratory	  depression.	  Dexmedetomidine	  exhibits	   poor	   oral	   bioavailability	   (Anttila	   et	   al.	   2003)	   and,	   therefore,	   alternative	  administration	   routes	   are	   needed.	   Previous	   studies	   have	   shown	   that	  dexmedetomidine	   is	   well	   absorbed	   intranasally	   (Iirola	   et	   al.	   2011),	  intramuscularly	  and	  buccally	   (Scheinin	  et	  al.	  1992;	  Anttila	  et	  al.	  2003).	  However,	  there	   are	   currently	   no	   data	   on	   the	   pharmacokinetics	   of	   dexmedetomidine	   after	  subcutaneous	  administration.	  	  The	  following	  literature	  review	  gives	  an	  insight	  on	  the	  anatomy	  and	  physiology	  of	  the	  autonomic	  nervous	  system	  and	  α2-­‐adrenergic	  receptors	  as	  a	  part	  of	  it.	  My	  aim	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is	   to	   describe	   the	   mechanism	   of	   action	   of	   α2-­‐receptor	   ligands,	   and	   the	  pharmacokinetics,	  pharmacodynamics	  and	   therapeutic	  uses	  of	  dexmedetomidine.	  Finally,	  basic	  knowledge	  of	  pharmacometric	  analysis,	  modeling	  and	  simulation	   is	  provided.	  	  In	   the	   experimental	   part	   of	   this	   thesis,	   the	   pharmacokinetics	   of	   subcutaneously	  and	   intravenously	   administered	   dexmedetomidine	   in	   healthy	   volunteers	   are	  investigated	   using	   pharmacokinetic	   analysis	   methods.	   Both	   explorative-­‐	   and	  noncompartmental	  pharmacokinetic	  analyses	  were	  conducted	  to	  obtain	  estimates	  for	   the	   pharmacokinetic	   parameters	   after	   subcutaneously	   and	   intravenously	  administered	   dexmedetomidine.	   Additionally,	   the	   pharmacometric	   analysis	   is	  performed	   to	   characterize	   the	   relationship	   between	   individual	   covariate	   effects	  and	  observed	  drug	  exposure.	  	  	  
2	  	  	  LITERATURE	  REVIEW	  	  2.1	  	  	  Autonomic	  nervous	  system	  	  The	   autonomic	   nervous	   system	   is	   the	   part	   of	   the	   nervous	   system	   that	   regulates	  essential	   body	   functions.	   It	   consists	   of	   nerves	   and	   nerve	   cells	   (Gabella	   2001),	  which	  principally	   innervate	   the	   smooth	  musculature	   of	   all	   organs,	   the	   heart	   and	  the	   endocrine	   glands	   (Jänig	   1989).	   Therefore,	   the	   autonomic	   nervous	   system	  mediates	   regulation	   of	   the	   internal	  milieu	   in	   the	   body.	   Compared	   to	   the	   somatic	  nervous	  system,	  which	  is	  under	  voluntary	  control,	  the	  autonomic	  nervous	  system	  is	  generally	  not	  voluntary	  controlled.	  	  Functionally,	  the	  autonomic	  nervous	  system	  can	  be	  divided	  into	  sympathetic-­‐	  and	  parasympathetic	   nervous	   system	   (Jänig	   1989).	   Both	   the	   sympathetic	   and	   the	  parasympathetic	   systems	   consist	   of	   preganglionic-­‐	   and	   postganglionic	   neurons,	  which	   transmit	   impulses	   to	   the	   effector	   tissue	   from	   the	   CNS	   (McCorry	   2007).	  Furthermore,	   the	  autonomic	  nervous	  system	  consists	  of	  another	  part;	   the	  enteric	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nervous	   system,	   which	   is	   confined	   to	   the	   gastrointestinal	   tract	   (Jänig	   1989).	   It	  regulates	   the	   motility	   and	   secretory	   activities	   in	   the	   gastrointestinal	   tract.	  However,	   it	   functions	   independently	   and	  no	   extrinsic	   input	   from	   the	   spinal	   cord	  and	  brainstem	  is	  needed.	  	  An	   autonomic	   nervous	   system	   consists	   of	   central	   and	   peripheral	   components	  (Gabella	  2001).	   In	   the	  central	  nervous	  system	  (CNS),	  nuclei	   in	   the	  hypothalamus,	  brainstem	  and	  spinal	  cord	  connect	  with	  afferent	  nerves	  to	  the	  peripherally	  located	  ganglia	  and	  further	  on	  with	  peripheral	  autonomic	  nerves.	  The	  nerves	  emerging	  out	  of	   the	   brainstem	   and	   spinal	   cord	   consist	   of	   a	   preganglionic-­‐	   and	   postganglionic	  neuron,	  and	  the	  autonomic	  ganglion,	   located	  outside	  the	  CNS,	  connects	  these	  two	  neurons	   by	   a	   synapse	   (McCorry	   2007).	   The	   preganglionic	   neurons	   are	   afferent	  neurons	   projecting	   from	   the	   nuclei	   in	   the	   CNS.	   The	   postganglionic	   neurons	   are	  axons	  projected	  from	  the	  ganglia	  to	  the	  peripheral	  tissues,	  such	  as	  smooth	  muscle	  cells,	  cardiac	  muscle	  and	  secretory	  cells	  (Jänig	  1989).	  	  	  The	  autonomic	  nervous	   system	   is	   involved	   in	   the	   regulation	  of	   several	  organs	   in	  the	  body.	  It	  controls,	  for	  example,	  the	  contraction	  and	  relaxation	  of	  the	  heart	  and	  arteries,	  movement	  of	   the	   iris	  and	   lens	   in	   the	  eye,	  urination	   in	   the	   lower	  urinary	  tract,	  and	  movement	  of	  hair	  and	  the	  secretion	  of	  sweat	  in	  the	  skin	  (Gabella	  2001).	  Furthermore,	   it	  mediates	  regulation	  in	  the	  gastrointestinal	  tract,	  genital	  tract	  and	  part	  of	  the	  airways.	  Many	  tissues	  are	  innervated	  by	  both	  the	  parasympathetic	  and	  the	   sympathetic	   nervous	   system,	   which	   typically	   possess	   opposing	   effects	   on	   a	  given	   tissue	   (McCorry	   2007).	   For	   example,	   in	   the	   heart	   the	   sympathetic	   system	  increases	  the	  heart	  rate,	  whereas	  the	  parasympathetic	  system	  decreases	  it.	  	  	  2.1.1	  Parasympathetic	  nervous	  system	  	  The	  parasympathetic	  preganglionic	  neurons	  emerge	  out	  from	  several	  nuclei	  of	  the	  brainstem	  and	  from	  the	  sacral	  region	  of	  the	  spinal	  cord,	  segments	  S2-­‐S4,	  as	  can	  be	  seen	  in	  Figure	  1	  (McCorry	  2007).	  The	  preganglionic	  axon	  of	  the	  neuron	  is	  long	  and	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synapses	  with	   the	  ganglia,	  which	   is	  near	  or	   in	   the	   effector	  organ	   (Figure	  1).	  The	  postganglionic	   neuron	   is,	   on	   the	   other	   hand,	   very	   short	   and	   is	   the	   neuron	   that	  provides	  input	  to	  the	  cells	  of	  the	  effector	  tissue.	  
Figure 1. The sympathetic and parasympathetic branches of the autonomic nervous 
system. The sympathetic preganglionic nerves (red) emerge out from the thoracic and 
lumbar regions of the spinal cord (segment T1 to L2). The preganglionic nerves connect 
to the postganglionic nerve/nerves (light red), by synapsis in the ganglia, which further 
innervates the effector organ. The parasympathetic preganglionic nerves (dark grey) 
emerge out from the brainstem and sacral region of the spinal cord (segment S2 to S4). 
The preganglionic nerve connects to the postganglionic nerve (light grey), by synapsis 
in the ganglia, which further innervates the effector organ. (Adapted from Jänig, 1989) 	  In	   the	   brainstem	   the	   emerging	   neurons	   exit	   the	   CNS	   through	   the	   cranial	   nerve	  (McCorry	  2007).	  The	  oculomotor	  nerve	  (III)	   innervates	   the	  eyes;	   the	   facial	  nerve	  (VII)	  innervates	  the	  lacrimal	  gland,	  the	  salivary	  glands	  and	  the	  mucus	  membranes	  of	   the	   nasal	   cavity;	   the	   glossopharyngeal	   nerve	   (IX)	   innervates	   the	   parotid	  (salivary)	  gland;	  and	  the	  vagus	  nerve	  (X)	  innervates	  the	  viscera	  of	  the	  thorax	  and	  the	  abdomen,	  for	  example,	  heart,	   lungs,	  stomach,	  pancreas,	  small	   intestine,	  upper	  half	   of	   the	   large	   intestine	   and	   liver.	   The	   preganglionic	   neurons	   from	   the	   sacral	  region	  of	   the	   spinal	   cord	  exit	   the	  CNS	  separately	  and	  are	   later	  united	   (Figure	  1),	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forming	  the	  pelvic	  nerves	  (McCorry	  2007).	  These	  nerves	  innervate	  the	  lower	  half	  of	  the	  large	  intestine	  and	  urogenital	  organs.	  	  The	  signal	  from	  the	  preganglionic	  neuron	  to	  the	  postsynaptic	  neuron	  and	  finally	  to	  the	   effector	   tissue	   is	   mediated	   through	   release	   of	   chemical	   transmitters	   in	   the	  synapses	  (McCorry	  2007).	  In	  the	  parasympathetic	  nervous	  system,	  acetylcholine	  is	  the	   principal	   neurotransmitter.	   Acetylcholine	   is	   released	   from	   the	   preganglionic	  nerve	   terminal	   at	   the	   ganglionic	   site,	   as	   well	   as	   from	   the	   postganglionic	   nerve	  terminal	  to	  affect	  the	  effector	  tissue.	  	  	  Receptors	  at	  the	  postganglionic	  neurons	  and	  effector	  tissues	  mediate	  the	  effect	  by	  binding	   of	   acetylcholine	   (McCorry	   2007).	   These	   receptors	   are	   muscarinic	   and	  nicotinic	   receptors.	   The	   muscarinic	   receptor	   is	   located	   at	   the	   effector	   tissue,	  whereas	  the	  nicotinic	  receptor	  is	  located	  in	  the	  postganglionic	  nerve.	  	  2.1.2	  Sympathetic	  nervous	  system	  	  The	  preganglionic	  neurons	  of	  the	  sympathetic	  nervous	  system	  originates	  from	  the	  thoracic	  and	  lumbar	  regions	  (Th1-­‐L1)	  of	  the	  spinal	  cord	  (McCorry	  2007),	  as	  can	  be	  seen	   in	   Figure	   1.	   Compared	   to	   the	   parasympathetic	   nervous	   system	  most	   of	   the	  preganglionic	   neurons	   are	   short	   and	   located	   remotely	   from	   the	   effector	   tissue.	  However,	   a	   few	   ganglia	   are	   known	   to	   be	   located	   near	   the	   pelvic	   organs,	   which	  therefore,	  send	  out	  short	  postganglionic	  neurons	  (Jänig	  1989).	  	  As	   can	   be	   seen	   in	   Figure	   1,	   a	   single	   preganglionic	   neuron	   may	   synapse	   with	  numerous	   postganglionic	   neurons.	   The	   ratio	   of	   preganglionic	   neurons	   to	  postganglionic	   neurons	   is	   about	   1:20,	   compared	   to	   the	   parasympathetic	   ratio	   of	  1:1	  (McCorry	  2007).	  This	  phenomenon	  is	  called	  divergence	  (Gabella	  2001)	  and	  it	  results	   in	   coordinated	   sympathetic	   stimulation	   to	   tissues	   throughout	   the	   body	  (McCorry	  2007).	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The	  sympathetic	  nervous	  system	  regulates	  essentially	  the	  same	  organs	  and	  tissues	  as	   the	   parasympathetic	   nervous	   system	   (Figure	   1).	   The	   sympathetic	   neurons	  additionally	  innervate	  the	  skin,	  its	  blood	  vessels	  and	  sweat	  glands,	  controlling	  the	  sweating	   and	   the	   tonus	   of	   the	   vascular	   smooth	   muscle	   (McCorry	   2007).	   These	  effects	   are	   only	   regulated	   by	   the	   sympathetic	   nervous	   system.	   Furthermore,	   the	  sympathetic	  neurons	  also	  innervate	  adipose	  tissue,	  the	  liver	  (Jänig	  1989)	  and	  the	  adrenal	  medulla	  (McCorry	  2007).	  	  In	   the	   sympathetic	   nervous	   system,	   the	   short	   preganglionic	   neurons	   are	  cholinergic	  and	  the	   long	  postganglionic	  neurons	  are	  adrenergic	  neuron	  (McCorry	  2007).	   Acetylcholine	   is	   released	   into	   the	   synaptic	   cleft	   from	   the	   preganglionic	  neuron	   to	   transport	   the	   signal	   to	   the	   postsynaptic	   sites,	   whereas	   in	   the	  postganglionic	  neuron	  terminal	  noradrenaline	  is	  released	  to	  mediate	  the	  effect	  on	  the	  target	  tissue.	  	  	  	  2.2	  Adrenergic	  receptors	  	  Adrenergic	   receptors	   are	   located	   in	   a	   large	   number	   of	   tissues,	   and	   connect	   the	  central-­‐	  and	  peripheral	  nervous	  systems	  (McCorry	  2007).	  The	  numerous	  metabolic	  and	  neuroendocrine	  effects	  of	   the	  catecholamines,	  noradrenaline	  and	  adrenaline,	  are	  mediated	  through	  interactions	  with	  two	  major	  classes	  of	  adrenergic	  receptors	  (Bylund	  1992:	  Strosberg	  1993).	  These	  two	  classes	  are	  the	  alpha	  (α-­‐)	  and	  the	  beta	  (β)-­‐adrenergic	   receptor	   (Ahlquist	   1948),	   which	   were	   discovered	   in	   1948	   by	  Alhquist	  based	  on	  the	  order	  of	  potency	  of	  several	  catecholamine	  analogues.	  	  In	  1986,	  Dixon	  and	  his	  co-­‐workers	  discovered	  that	  the	  β-­‐adrenergic	  receptor,	  like	  rhodopsin,	  obtained	  a	  seven-­‐transmembrane	  structure	  (7TM)	  (Dixon	  et	  al.	  1986).	  The	  discovery	  leads	  to	  the	  idea	  that	  a	  large	  gene	  family	  of	  receptors	  existed.	  This	  gene	  family	  was	  later	  named	  the	  G-­‐protein-­‐coupled	  receptor	  (GPCR)	  –superfamily,	  to	   which	   all	   adrenergic	   receptors	   nowadays	   belong	   (Bylund	   1992:	   Storsberg	  1993).	  The	  amino	  acids	  that	  build	  up	  the	  transmembrane	  receptor	  crosses	  the	  cell	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membrane	   seven	   times	   and	   incorporates	   hydrophilic	   and	   hydrophobic	   areas	  (Khan	   et	   al.	   1999).	   Additionally,	   to	   the	   seven	   hydrophobic	   transmembrane	  segments,	   the	   intracellular	   carboxyl	   terminus	   and	   the	   extracellular	   amino	  terminus	   are	   the	   common	   structural	   feature	   for	   the	   different	   GPCRs	   (Kobilka	  2007).	  A	  cartoon	  of	  a	  GPCR	  can	  be	  seen	  in	  Figure	  2.	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 2. A GPCR with its seven hydrophobic transmembrane segments (H1-H7), 
extracellular amino terminus (COOH-) and intracellular carboxyl terminus (NH3+). 
(Adapted from Lodish et al. 2000) 	  The	  α-­‐adrenergic	  receptor	  is	  further	  divided	  into	  α1-­‐	  and	  α2-­‐	  adrenergic	  receptors	  (Langer	  1974:	  Bylund	  and	  U´Prichard	  1983:	  Molinoff	  1984),	  which	  gives	  a	  total	  of	  three	  types	  of	  adrenergic	  receptors,	  namely,	  α1,	  α2	  and	  β.	  The	  different	  adrenergic	  receptors	   are	   42-­‐45	   %	   identical	   in	   terms	   of	   the	   amino	   acid	   sequence	   in	   the	  membrane	  domain	  (Khan	  et	  al.	  1999).	  This	  implies	  that	  the	  diversity	  in	  the	  amino	  sequence	   in	   the	   transmembrane	   region	   is	   important	   for	   the	   selectivity	   of	   ligand	  binding.	  	  	  2.2.1	  Beta	  adrenergic	  receptor	  	  The	   β-­‐adrenergic	   receptors	   can	   further	   be	   divided	   into	   β1-­‐	   and	   β2-­‐	   adrenergic	  receptor	   (Arnold	   et	   al.	   1966:	   Lands	   et	   al.	   1967a:	   Lands	   et	   al.	   1967b).	   The	   β1-­‐receptors	  are	  located	  in	  the	  heart,	  brain,	  and	  adipose	  tissues	  and	  have	  high	  affinity	  for	  both	  noradrenaline	  and	  adrenaline	  (Molinoff	  1984).	  For	  example,	  β1-­‐adrenergic	  stimulation	   in	   the	   heart	   and	   kidneys	   increase	   cardiac	   output	   and	   renin	   release,	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respectively	   (Giovannitti	   et	   al.	   2015).	   β2-­‐receptors	   are	   located	   in	   vascular	   and	  other	  smooth	  muscles,	  for	  example,	  bronchial	  smooth	  muscle	  cells	  (Giovannitti	  et	  
al.	   2015)	   and	   show	   low	   affinity	   for	   noradrenaline	   (Molinoff	   1984).	   The	  physiological	   functions	   of	   the	   β2	  receptors	   in	   the	   vascular	   and	   bronchial	   smooth	  muscles	   cells	   are	   vasodilatation	   and	   relaxation	   (Giovannitti	   et	   al.	   2015).	   An	  additional	  subtype	  of	  the	  β-­‐adrenergic	  receptor	  has	  been	  discovered,	  giving	  rise	  to	  three	   subtypes	   of	   the	   β-­‐adrenergic	   receptor.	   The	   β3-­‐receptor	   has	   been	   found	   to	  regulate	   the	   lipid	   metabolism	   in	   adipose	   tissue,	   which	   is	   very	   distinct	   from	   the	  other	  β-­‐adrenergic	  receptor	  subtypes	  (Strosberg	  1997:	  Giovannitti	  et	  al.	  2015).	  	  2.2.2	  Alpha-­‐1	  adrenergic	  receptor	  	  Similar	   to	   the	   β2-­‐receptors,	   the	   α1–adrenergic	   receptors	   are	   located	   in	   the	  postsynaptic	  site	  (Molinoff	  1984)	  of	   the	  vascular	  smooth	  muscle	  cells	  Giovannitti	  
et	   al.	   2015).	   However,	   the	   effects	   of	   the	   α1-­‐receptors	   are	   different	   as	   they	   are	  involved	  in	  the	  vasoconstriction	  of	  the	  vascular	  smooth	  muscle	  cells.	  	  	  2.2.3	  Alpha-­‐2	  adrenergic	  receptor	  	  The	   α2-­‐receptors	   have	   been	   located	   at	   both	   post-­‐	   and	   presynaptical	   site	   in	   the	  central-­‐	  and	  peripheral	  nervous	  system	  (Langer	  1981,	  Gertler	  et	  al.	  2001).	   In	   the	  CNS	  the	  presynaptical	  receptors	  are	   located	   in	  sympathetic	  nerve	  endings	  and	   in	  noradrenergic	   neurons,	   where	   they	   inhibit	   the	   release	   of	   noradrenaline	   when	  stimulated	   (Langer	   1981).	   In	   the	   peripheral	   the	   α2-­‐receptors	   are	   also	   located	   in	  noradrenaline	  nerve	  endings	  and	   inhibit	   the	  noradrenaline	  release.	  Furthermore,	  α2-­‐receptors	   exist	   peripherally	   in	   numerous	   tissues,	   for	   example	   in	   the	   liver,	  pancreas,	   platelets,	   kidney,	   eye	   and	   the	   adipose	   tissue	   (Khan	   et	   al.	   1999).	  Depending	   on	   the	   location,	   the	   physiologic	   responses	   mediated	   through	   the	   α2-­‐receptor	  vary	  significantly.	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High	   density	   of	   the	   α2-­‐receptor	   can	   be	   found	   in	   the	   medullary	   dorsal	   motor	  complex	  in	  the	  brain	  and	  in	  the	  locus	  coeruleus,	  which	  is	  the	  largest	  noradrenergic	  cell	   group	   in	   the	   brain	   (Dahlström	   and	   Fuxe	   1965:	   Khan	   et	   al.	   1999).	   Other	  locations	  shown	  to	  express	  a	  high	  density	  of	  α2-­‐	  adrenergic	  receptors	  include	  the	  substantia	   gelatinosa	   in	   the	   dorsal	   horn,	   intermediolateral	   column	   in	   the	   spinal	  tract	  and	  the	  vagus	  nerve	  (Khan	  et	  al.	  1999).	  	  	  It	   was	   long	   thought	   that	   the	   presynaptic	   plate	  was	   only	   linked	   to	   the	   synthesis,	  storage,	   release	   and	   inactivation	  of	   noradrenaline	   (Langer	  1981),	   and	   it	  was	  not	  assumed	   that	   receptors	  would	   be	   located	   in	   the	   presynaptic	  membrane.	   Later	   it	  was	  found	  that	  presynaptic	  receptors	  are	  expressed	  in	  addition	  to	  the	  postsynaptic	  receptors	   (Langer	   1974).	   The	   presynaptic	   α2-­‐receptors	   have	   tremendous	   clinical	  importance	   as	   they	   regulate	   the	   release	   of	   noradrenaline	   through	   a	   negative	  feedback	  mechanism.	  	  	  Based	  on	  the	  affinity	  for	  α2-­‐adrenergic	  receptor	  ligands,	  the	  α2-­‐adrenergic	  receptor	  can	  be	  divided	  into	  three	  different	  α2	  isoreceptors,	  namely,	  α2A,	  α2B,	  and	  α2C	  (Bylund	  1985,	  Blaxall	  et	  al.	  1991).	  These	  subtypes	  are	  72-­‐75	  %	   identical	   to	  each	  other	   in	  regard	  to	  the	  amino	  acid	  sequence	  of	  the	  membrane	  crossing	  section	  (Khan	  et	  al.	  1999).	  The	  different	  subtypes	  have	  been	  shown	  to	  mediate	  different	  effects	  in	  the	  body.	   The	   subtypes	   α2A	   and	  α2C,	  which	   are	   found	  mainly	   in	   the	   CNS,	   seem	   to	   be	  responsible	  for	  sedation,	  analgesia,	  and	  sympatholytic	  effects	  (Scheinin	  et	  al.	  1994:	  Hunter	   et	   al.	   1997:	   Buerkle	   and	   Yaksh	   1998).	   The	   α2B	   receptors	   are	   expressed	  more	   frequently	   in	   vascular	   smooth	   muscle	   cells,	   where	   they	   mediate	  vasoconstriction	  (Link	  et	  al.	  1997).	  	  	  2.3	  Alpha-­‐2	  adrenoceptor	  agonists	  	  α2-­‐receptor	  agonists	  have	  been	  used	  to	  treat	  common	  medical	  conditions	  such	  as	  hypertension,	   attention-­‐deficit/hyperactivity	   disorder	   (ADHD),	   pain	   and	   anxiety,	  withdrawal	  symptoms	  from	  long-­‐term	  drug	  abuse,	  cigarette	  craving	  (Giovannitti	  et	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al.	   2015).	   	  Recent	   research	  has	   focused	  on	   the	   sedative,	   analgesic,	   anxiolytic	  and	  sympatholytic	  effects	  of	  the	  α2-­‐receptor	  agonists	  (Scheinin	  et	  al.	  1989:	  Hunter	  et	  al.	  1997:	  Buerkle	  and	  Yaksh	  1998).	  	  	  Clonidine	   was	   the	   first	   α2-­‐adrenoceptor	   agonist	   on	   the	   market,	   and	   several	   α2-­‐receptor	  agonists	  have	   since	  been	  developed	   (Gertler	  et	  al.	   2001).	  Clonidine	  was	  introduced	   to	   the	  market	  as	  a	  nasal	  decongestant	   (Giovannitti	  et	  al.	  2015),	  but	   it	  caused	   severe	   hypotension,	   after	   which	   it	   gained	   a	   new	   clinical	   use	   in	   treating	  hypertension	   (Gertler	  et	  al.	   2001).	  Clonidine	  has	  also	  been	  used	   to	   treat	   anxiety,	  ADHD,	   chronic	   pain,	   withdrawal	   symptoms	   and	   postoperative	   shivering	  (Giovannitti	  et	  al.	  2015).	  Lately	  it	  has	  also	  been	  used	  as	  pretreatment	  for	  surgical	  patients	   with	   anxiety	   (Hall	   et	   al.	   2006)	   and	   for	   procedural	   sedation	   in	   children	  (Cao	  et	  al.	  2009).	  	  Other	  α2-­‐adrenoceptor	   agonists	   currently	   used	   in	   clinical	   practice	   are	   tizanidine,	  medetomidine	  and	  dexmedetomidine.	  These	  possess	   the	  sedative,	   anxiolytic,	   and	  analgesic	  properties	  similar	  to	  those	  of	  clonidine	  (Scheinin	  et	  al.	  1989:	  Giovannitti	  
et	  al.	  2015;	  Gertler	  et	  al.	  2001).	  Tizanidine	  has	  been	  used	  for	  treatment	  of	  muscle	  spasm	  and	  cramps,	  myofascial	  pain	  disorders	  of	  head	  and	  neck,	  and	  spasticity	  of	  cerebral	  palsy	  (Giovannitti	  et	  al.	  2015).	  Medetomidine	  is	  nowadays	  mainly	  used	  in	  veterinary	   medicine	   to	   sedate	   cats	   and	   dogs	   (Scheinin	   et	   al.	   1989).	  Dexmedetomidine	  is	  the	  pharmacologically	  active	  d-­‐enantiomer	  of	  medetomidine	  (Savola	  and	  Virtanen	  1991)	  and	  it	   is	  used	  as	  a	  sedative	   in	  the	  intensive	  care	  unit	  (ICU)	  (Approval	  letter:	  Precedex®	  1999).	  	  2.3.1	  Mechanism	  of	  action	  	  As	   previously	  mentioned	   the	   clinical	   effects	   of	   the	   α2-­‐adrenoceptor	   agonists	   are	  produced	  after	  binding	  to	  the	  α2-­‐adrenoceptor.	  All	  subtypes	  of	  the	  α2-­‐receptor	  are	  GPCR	  (Bylund	  1992:	  Storsberg	  1993),	  and	  the	  effect	  is	  mediated	  through	  activation	  of	   G-­‐	   (guanine-­‐nucleotide	   regulatory	   binding)	   proteins	   (Freissmuth	   et	   al.	   1989)	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These	  G-­‐proteins	  consist	  of	   three	  subunits;	   the	  beta	  subunit;	   the	  gamma	  subunit;	  and	   the	   alpha	   subunit,	   which	   binds	   the	   guanine	   nucleotides,	   guanosine	  diphosphate	   (GDP)	   and	   guanosine	   triphosphate	   (GTP)	   (Codina	   et	   al.	   1987:	  Freissmuth	  et	  al.	  1989).	  	  At	  a	  resting	  state,	  when	  the	  α2-­‐receptor	   is	  not	  activated,	   the	  GDP	   is	  bound	  to	   the	  alpha	   subunit	   of	   the	  G-­‐protein,	   and	   the	  G-­‐protein	   is	  not	   attached	   to	   the	   receptor	  (Khan	   et	   al.	   1999).	   After	   an	   agonist	   binds	   to	   the	   receptor,	   a	   structural	   change	  occurs,	   and	   the	   G-­‐protein	   is	   coupled	   to	   the	   receptor.	   The	   activation	   results	   in	  decreased	  affinity	  for	  GDP	  and	  subsequently	  GDP	  is	  replaced	  by	  GTP,	  causing	  the	  dissociation	   of	   the	   alpha	   subunit	   from	   the	   beta	   and	   gamma	   subunit,	   thus	  generating	   a	   separate	   alpha	   subunit	   and	   a	   beta-­‐gamma	   complex	   (Codina	   et	   al.	  1987:	  Neer	  and	  Clapham	  1988).	  	  	  Activated	   G-­‐protein	   (or	   Gi-­‐protein)	   inhibits	   adenylyl	   cyclase	   (Freissmuth	   et	   al.	  1989),	   which	   further	   results	   in	   decreased	   formation	   of	   3´5´-­‐	   cyclic	   adenosine	  monophosphate	  (cAMP)	  (Figure	  3).	  The	  inhibition	  of	  adenylyl	  cyclase	  is	  an	  almost	  ubiquitous	  effect	  seen	  in	  many	  different	  G-­‐protein	  associated	  receptors	  (Khan	  et	  al.	  1999).	   However,	   all	   physiological	   effects	   mediated	   by	   α2	   adrenergic	   receptor	  cannot	  be	  explained	  by	  the	  decrease	  of	  intracellular	  cAMP.	  	  	  α2-­‐receptor	  activation	  also	  results	  in	  the	  hyperpolarization	  of	  the	  cell	  membrane,	  which	  is	  caused	  by	  the	  modulation	  of	  ion	  channel	  activity.	  The	  activation	  of	  the	  G1-­‐protein,	   which	   gates	   the	   potassium	   channels,	   results	   in	   efflux	   of	   potassium	   ions	  (Figure	   3)	   (Codina	   et	   al.	   1987)	   The	   efflux	   of	   potassium	   ions	   causes	  hyperpolarization	  of	  the	  cell	  membrane	  and	  prevents	  neuronal	  firing	  (Aghajanian	  and	  VanderMaelen,	  1982).	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Figure 3. Stimulation of the presynaptic α2ABC adrenergic receptor. When the 
presynaptic α2 adrenergic receptor binds its ligand, the G-protein, consisting of the 
alpha, beta and gamma subunit, is coupled to the receptor. This results in a) inhibition 
of adenylyl cyclase, which decreases the formation of 3,5-cyclic adenosine 
monophosphate (cAMP). b) efflux of potassium, causing hyperpolarization and c) 
dissociation of the alpha subunit from the beta and gamma subunit, which results in 
inhibition of calcium influx by the beta and gamma subunit. (Adapted from Gilsbach 
and Hein 2008) 	  	  Neurotransmitter	   release	   from	   the	   synapse	   is	   controlled	   by	   voltage-­‐dependent	  calcium	   ion	   channels,	   which	   are	   coupled	   to	   the	   G-­‐protein	   G0	   (Bean	   1989:	  Birnbaumer	  et	  al.	  1990).	  When	  activated	  the	  subunits	  of	  the	  G-­‐protein	  dissociate,	  and	  the	  beta-­‐gamma	  complex	  mediates	  the	  effect	  of	  α2–agonists	  further	  on	  to	  the	  calcium	   ion	   channel	   (Figure	   3)	   (Herlitze	   1996:	   Ikeda	   1996).	   The	   beta-­‐gamma	  complex	   inhibits	   calcium	   influx	   through	   the	   calcium	   ion	   channel,	   resulting	   in	  inhibition	   of	   neurotransmitter	   release.	   Hence,	   the	   negative	   feedback	  mechanism	  mediated	  by	  the	  α2–agonists	  prevents	  the	  nerve	  from	  constant	  firing	  and	  inhibits	  the	  release	  of	  neurotransmitters,	  both	  of	  which	  cause	  a	  reduction	  of	  the	  activity	  in	  the	  ascending	  noradrenergic	  pathways.	  	  	  The	  α2-­‐adrenoceptor	  agonist	  affects	  both	  central	  and	  peripheral	  nervous	  systems	  by	   modulating	   autonomic	   nervous	   system	   functions.	   The	   central	   effects	   can	   be	  seen	   in	   attenuating	   sympathetic	   responses	   like	   hypertension	   and	   tachycardia	   by	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stimulation	  of	   the	  α2-­‐adrenoceptor	   located	  post-­‐synaptically	  (Gertler	  et	  al.	  2001).	  The	   sedative	   and	   analgesic	   actions	   of	   α2-­‐adrenoceptor	   agonists	   are	   mediated	  through	   the	   α2A-­‐adrenergic	   receptor	   subtype	   in	   the	   CNS	   (Hunter	   et	   al.	   1997:	  Lakhlani	   et	  al.	   1997),	  whereas	   the	   anxiolytic	   effect	   is	  mediated	   through	   the	   α2C-­‐adrenergic	  receptor	  subtype	  (Figure	  4)	  (Sallinen	  et	  al.1998).	  The	  sedative	  effect	  is	  mediated	   through	   locus	   coeruleus,	   which	   is	   an	   important	   modulator	   of	  wakefulness	   (Scheinin	   and	   Schwinn	   1992:	   Gertler	   et	   al.	   2001).	   	   The	   analgesic	  effects	   are	  mediated	   through	   the	   substantia	   gelatinosa	   of	   the	   dorsal	   horn	   in	   the	  spinal	   cord	   (Kuraishi	   et	   al.	   1985),	   and	   through	   the	   descending	   medullospinal	  noradrenergic	   pathway,	  which	   has	   its	   origin	   in	   locus	   coeruleus.	   (Marwaha	   et	  al.	  1983:	  Gertler	  et	  al.	  2001).	  	  	  Activation	   of	   the	   peripherally	   located	   α2-­‐adrenergic	   receptors	   causes	   various	  physiological	   effects.	   In	   the	   gastrointestinal	   tract	   the	   effects	   include	   decreased	  salvation,	  endocrine	  secretion,	  and	  bowel	  motility	  (Khan	  et	  al.	  1999:	  Gertler	  et	  al.	  2001).	   Inhibition	   of	   renin	   release,	   increased	   glomerular	   filtration,	   and	   increased	  secretion	  of	   sodium	  and	  water	   are	   seen	   in	   the	   kidney.	   α2-­‐adrenergic	   stimulation	  decreases	   intraocular	   pressure	   and	   insulin	   release	   from	   the	   pancreas,	   and	  contracts	   vascular	   and	   other	   smooth	  muscle.	   The	   release	   of	   growth	   hormone	   is	  increased,	   and	   α2-­‐adrenergic	   receptors	   inhibit	   the	   lipolysis	   of	   adipose	   tissue,	  decrease	  the	  amount	  of	  circulating	  catecholamines	  in	  plasma,	  and	  it	  has	  also	  been	  shown	   that	   a	   high	   concentration	   of	   the	   α2-­‐adrenoceptor	   agonists	   causes	   platelet	  aggregation	  (Khan	  et	  al.	  1999).	  	  	  In	   opposite	   to	   the	   centrally	   located	   α2-­‐adrenoceptors,	   which	   by	   sympatholysis	  mediates	   hypotension	   and	   bradycardia	   (Gertler	   et	   al.	   2001),	   the	   peripherally	  located	   α2-­‐adrenoceptors	   generates	   vasoconstriction.	   It	   is	   the	   α2B-­‐adrenergic	  receptor	   subtype	   that	   is	   responsible	   for	   this	   effect,	   and	   it	   is	   located	  postsynaptically	  in	  the	  vascular	  smooth	  muscle	  cells	  (van	  Meel	  et	  al.1981:	  Link	  et	  
al.	  1997).	  Additional	  receptor	  subtypes	  and	  their	  effects	  are	  shown	  in	  Figure	  4.	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Figure 4.  The pharmaceutical effects of α2-adrenoceptor agonist in various organs in 
the human body mediated through different α2-adrenoceptor subtypes. Sedation and 
anxiolysis are mediated through the binding to α2A- and α2C-adrenoceptors, respectively, 
located in the CNS. The analgesic effect is mediated through the binding of the agonist 
to the α2A-adrenoceptor subtype in the spinal cord. Vasoconstriction is mediated through 
the α2B-adrenoceptor subtype, whereas vasodilation is mediated through sympatholysis, 
however, unsure of the subtype. The bradycardic effect is mediated through the α2A-
adrenoceptor subtype, whereas it is not certain if tachycardia is mediated through the 
α2B-adrenoceptor subtype. The mechanism for anti-shivering and diuresis are unknown. 
(Adapted from Kaur M, Singh P-M, 2011) 	  	  2.4	  Dexmedetomidine	  	  Dexmedetomidine	  (Figure	  5)	  is	  the	  pharmacologically	  active	  enantiomer	  of	  the	  α2-­‐adrenoceptor	   agonist	   medetomidine	   (Savola	   and	   Virtanen	   1991),	   and	   it	   is	   a	  specific	  and	  potent	  α2-­‐adrenoceptor	  agonist	  (Aantaa	  et	  al.	  1993)	  with	  a	  wide	  range	  of	   pharmacological	   properties,	   such	   as	   sympatholysis,	   sedation,	   anxiolysis,	   and	  analgesia	   (Gertler	   et	   al.	   2001).	   The	   high	   selectivity	   of	   dexmedetomidine	   results	  from	   its	   greater	   affinity	   for	   the	   α2-­‐adrenoceptor	   compared	   to	   clonidine.	  Dexmedetomidine	   is	   approximately	   eight	   times	   more	   selective	   to	   the	   α2-­‐
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adrenoceptor	   than	   clonidine,	   as	   clonidine	   has	   a	   specificity	   of	   220:1	   to	   the	   α2-­‐adrenoceptor,	  compared	  to	  1620:1	  with	  dexmedetomidine	  (Gertler	  et	  al.	  2001).	  	  	  	  	  	  	  	  	  	  
Figure 5. The chemical structure of dexmedetomidine (Product monograph: Precedex® 
2016) 	  2.4.1	  Pharmacological	  effects	  	  The	   primary	   and	   desired	   pharmacological	   effects	   of	   dexmedetomidine	   are	  mediated	   through	  binding	  of	   the	  agonist	   to	   the	  α2-­‐adrenergic	   receptor	   located	   in	  CNS.	   	   The	   binding	   of	   dexmedetomidine	   in	   CNS	   causes	   sedation,	   analgesia,	  anxiolysis	  and	  sympatholysis	  by	  the	  mechanism	  previously	  described.	  Thereby,	   it	  can	  be	  used	  in	  a	  wide	  range	  of	  clinical	  settings.	  	  The	   dose-­‐dependent	   sedative	   effect	   of	   dexmedetomidine	   has	   been	   well	  documented	  (Afonso	  and	  Reis	  2012).	  Dexmedetomdine	  has	  also	  been	  described	  to	  produce	  even	  anesthesia	  when	  increased	  doses	  are	  given,	  which	  suggested	  that	  it	  could	  be	  used	  as	  an	  intravenous	  (IV)	  anesthetic	  (Ebert	  et	  al.	  2000).	  Furthermore,	  the	  sedation	  induced	  by	  dexmedetomidine	  showed	  similarity	  with	  natural	  sleep,	  as	  the	   sleeping	   pattern	   is	   identical	   with	   the	   natural	   course	   of	   sleep	   (Nelson	   et	   al.	  2003).	  	  After	   dexmedetomidine	   dosing,	   a	   brief	   biphasic	   and	   dose-­‐dependent	   stimulatory	  effect	   on	   the	   cardiovascular	   system	   is	   observed	   (Bloor	  et	  al.	   1992,	   Penttilä	  et	  al.	  2004).	   	   First,	   a	   short	   hypertensive	   phase	   is	   seen	   followed	   by	   hypotension.	   The	  initial	  increase	  in	  blood	  pressure	  and	  reflectory	  decrease	  in	  the	  heart	  rate	  are	  seen	  after	   a	   bolus	   dose	   of	   1	   μg/kg	   (Bloor	   et	  al.	   1992).	   The	   hypertensive	   effect	   to	   the	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hemodynamics	   is	   caused	   by	   stimulation	   of	   the	   α2B-­‐adenoceptor	   in	   the	   vascular	  smooth	   muscle,	   whereas	   the	   observed	   decrease	   in	   blood	   pressure	   after	   5-­‐10	  minutes	  is	  due	  to	  the	  induction	  of	  the	  sympathetic	  tone	  (Bloor	  et	  al.	  1992:	  Link	  et	  
al.	   1997).	   Furthermore,	   the	   dose-­‐dependent	   bradycardic	   effect	   is	   also	   primarily	  meditated	   by	   sympatholysis	   (Gertler	   et	   al.	   2001).	   However,	   with	   doses	   ranging	  from	   0.25	   μg/kg	   to	   0.5	   μg/kg	   only	   a	   slight	   reduction	   of	   blood	   pressure	   was	  obtained	  (Bloor	  et	  al.	  1992).	  	  	  Dexmedetomidine	  has	  a	  minimal	  effect	  on	  the	  respiratory	  system,	  which	  should	  be	  considered	  as	  a	  major	  advantage	  compared	  with	  other	  anesthetic	  drugs	  (Ebert	  et	  
al.	  2000:	  Petroz	  et	  al.	  2006).	  Even	  when	  plasma	  concentrations	  are	  up	  to	  15	  times	  higher	   than	   the	   therapeutic	   range,	   only	   limited	   respiratory	   effects	   result,	   which	  gives	   dexmedetomidine	   wide	   safety	   margins	   (Venn	   et	   al.	   2000).	   When	  dexmedetomidine	   is	   used	   in	   ICU,	   no	   adverse	   effects	   on	   respiratory	   rate	   and	   gas	  exchange	   have	   been	   demonstrated	   on	   the	   spontaneously	   breathing	   surgical	  patients.	   Additionally,	   it	   is	   suggested	   that	   dexmedetomidine	   possesses	  neuroprotective	  properties	  by	  reducing	  catecholamine	  release	  (Ding	  et	  al.	  2015).	  It	  also	   reduces	   cerebral	   blood	   flow	   and	   cerebral	   oxygen	   consumption	   (Kaur	   and	  Singh	  2011).	  	  2.4.2	  Pharmacokinetics	  	  When	  dexmedetomidine	  is	  administered	  at	  the	  recommended	  dose	  range	  of	  0.2	  to	  0.7	  μg/kg/hr	  it	  exhibits	  linear	  pharmacokinetics	  (Product	  monograph:	  Precedex®	  2016),	   in	   other	   words,	   a	   constant	   fraction	   of	   the	   drug	   is	   eliminated	   per	   hour	  instead	  of	  a	  constant	  fraction	  of	  the	  drug	  per	  hour.	  The	  onset	  of	  dexmedetomidine	  effect	  after	  an	  IV	  administration	  varies	  from	  10-­‐15	  minutes	  (Product	  monograph:	  Precedex®	  2016),	  and	  during	  continuous	  infusion	  a	  peak	  concentration	  is	  usually	  achieved	  within	  1	  hour	   (Afonso	  and	  Reis	  2012).	  Other	  administration	  modalities	  can	   also	   be	   used,	   since	   dexmedetomidine	   is	   sufficiently	   absorbed	   after	  intramuscular	   (IM),	   oral,	   buccal,	   transdermal	   and	   intranasal	   (IN)	   administration	  (Kivistö	  et	  al.	  1994;	  Anttila	  et	  al.	  2003).	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  Dexmedetomidine	  exhibits	  a	  plasma	  protein	  binding	  of	  94	  %,	  which	  has	  shown	  to	  be	   constant	   over	   the	   concentration	   range	   of	   0.85	   to	   85	   ng/ml	   (Dexdor®	   INN-­‐dexmedetomidine).	  It	  is	  bound	  to	  both	  α1-­‐glycoprotein	  and	  human	  serum	  albumin,	  to	  which	  the	  latter	  majority	  of	  the	  binding	  occurs.	  	  	  	  The	   bioavailability	   of	   the	   different	   administration	   routes	   has	   been	   characterized	  (Anttila	  et	  al	  2003)	  and	  the	  highest	  bioavailability	  was	  obtained	  from	  the	  IM	  route,	  with	  a	  value	  of	  104	  %.	   	  However,	   in	  another	  study	  a	  bioavailability	  of	  73	  %	  was	  obtained	   for	   the	   IM	   route	   (Dyck	   et	   al.	   1993b).	   	   The	   oral	   bioavailability	   for	  dexmedetomidine	   is	   low,	  15.6	  %	  after	  oral	  administration.	  However,	  after	  buccal	  administration	   dexmedetomidine	   shows	   high	   bioavailability	   (82	   %).	   The	  bioavailability	  for	  transdermal	  and	  IN	  administrations	  have	  also	  been	  studied.	  The	  bioavailability	   of	   transdermally	   administered	   dexmedetomidine	   from	   the	  transdermal	  patch	  was	  51	  %.	  However,	  after	  dexmedetomidine	  was	  released	  from	  the	   preparation	   and	   localized	   transdermally	   it	   showed	   a	   bioavailability	   of	   88	  %	  (Kivistö	   et	   al.	   1994).	   In	   the	   bioavailability	   study	   of	   IN	   administered	  dexmedetomidine	   the	   median	   absolute	   bioavailability	   was	   obtained	   for	  dexmedetomidine,	  with	  a	  value	  of	  65	  %	  (Iirola	  et	  al.	  2011).	  However,	  there	  was	  a	  large	  inter-­‐individual	  variation,	  as	  the	  values	  range	  from	  35	  %	  to	  93	  %.	  	  Yoo	  et	  al.	  (2015)	  have	  also	   studied	   the	   intranasal	  administration	   route	   through	  population	  modeling.	  The	  obtained	  bioavailability	  was	  higher,	  namely	  82	  %.	  The	  results	  from	  previously	  mentioned	  studies	  have	  been	  summarized	  in	  Table	  1.	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Table 1. The bioavailability for different administration routes. Dyck et al. 1993b1), 
Kivistö et al. 1994 2), Anttila et al. 20033), Iirola et al. 2011 4), Yoo et al. 2015 5) 	   Route	  of	  administration	   F	  (%)	  IM	   103.6	  3)	  73	  1)	  Buccal	   81.8	  3)	  Intranasal	   65.4	  4),	  82	  5)	  Transdermal	   88	  2)	  Peroral	   15.6	  3)	  	  Due	   to	   its	   high	   lipophilicity,	   dexmedetomidine	   is	   rapidly	   distributed	   into	   tissues	  with	  a	  distribution	  half-­‐life	  of	  approximately	  6	  minutes,	  which	  explains	  the	  rapid	  onset	  of	  action	  (Karol	  and	  Maze	  2000,	  based	  on	  the	  Abbott	  Laboratories	   internal	  report	  by	  Karol	  1998:	  Anttila	  et	  al.	  2003:	  Product	  monograph:	  Precedex® 2016).	  The	   steady-­‐state	   volume	   of	   distribution	   (Vss)	   varies	   according	   to	   these	   authors	  from	  97.3	  ±	  29	  l	  to	  121	  ±	  20	  l.	  	  	  In	   previous	   studies,	   clearance	   (CL)	   for	   the	   different	   administration	   routes	   were	  obtained	  and	  shown	  in	  Table	  2.	  The	  values	  range	  between	  39	  and	  49.2	  L/h	  after	  IV	  administration,	   whereas	   apparent	   clearance	   (CL/F)	   for	   IN,	   transdermal	   and	   IM	  varies	  from	  41.8	  to	  63	  L/h.	  In	  Table	  2	  the	  elimination	  half-­‐life	  (t1/2)	  is	  additionally	  shown.	  The	   elimination	  half-­‐lives	   varied	   from	  1.9	  h	   to	  up	   to	  5.6	  h.	  However,	   the	  elimination	  half-­‐life	  average	  from	  the	  previous	  studies	  was	  approximately	  2.5	  h.	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Table 2. The average clearance (CL) and elimination half-life (t1/2) for the different 
routes of administration obtained from different studies. Scheinin et al. 1992 * with an 
average of 70 kg 1), Kivistö et al. 1994 2), Karol and Maze 2000 based on Karol 1998 3), 
Anttila et al. 2003 4), Iirola et al. 2011 5), Yoo et al. 2015 6), Product monograph: 
Precedex® Hospira 2016 7) 	   Route	   of	  administration	   CL	  (L/h)	   t1/2	  (h)	  IV	   39	  7)	  	  39.4	  3)	  40.9	  5)	  47.4	  4)	  	  	  49.2	  2)	  	   1.9	  5)	  2	  7)	  2.1	  3)	  2.17	  4)	  3.12)	  	  	   CL/F	  (L/h)	   	  IM	   49-­‐63*	  1)	   1.6-­‐2.5	  1)	  2.5	  4)	  Buccal	   -­‐	   1.9	  4)	  IN	   44.0	  6)	  46.1	  5)	  	   1.9	  5)	  Transdermal	   41.8	  2)	   5.6	  2)	  	  	  Dexmedetomidine	   is	   eliminated	   mainly	   through	   liver	   biotransformation	   and	  excreted	  in	  the	  urine	  (Product	  monograph:	  Precedex®	  2016).	  When	  radiolabeled	  dexmedetomidine	   was	   administered	   intravenously,	   an	   average	   of	   95	   %	   of	   the	  radioactivity	  was	   recovered	   in	   the	   urine	   after	   9	   days	   and	   only	   4	  %	   in	   the	   feces.	  Already	  after	  24	  hours,	  approximately	  85	  %	  of	  the	  radioactivity	  was	  recovered	  in	  the	  urine.	  Additionally,	  no	  unchanged	  dexmedetomidine	  was	  excreted.	  	  Dexmedetomidine	  is	  almost	  completely	  biotransformed	  in	  the	  liver	  through	  direct	  N-­‐glucuronidation	   and	   cytochrome	   P450	   enzyme-­‐mediated	   aliphatic	  hydroxylation	  (Product	  monograph:	  Precedex®).	  Metabolites	  detected	  in	  the	  urine	  were	   mainly	   products	   of	   N-­‐glucuronidation	   (34	   %).	   Aliphatic	   hydroxylation	   of	  dexmedetomidine	   produces	   3-­‐hydroxy-­‐dexmedetomidine	   and	   3-­‐carboxylic	   acid-­‐dexmedetomidine,	  which	  account	  for	  approximately	  14	  %	  of	  the	  dose	  excreted	  into	  urine.	   Additionally	   dexmedetomidine	   was	   metabolized	   through	   N-­‐methylation	  forming	   3	   hydroxy	   N-­‐methyl	   dexmedetomidine,	   3-­‐carboxy	   N-­‐methyl	  dexmedetomidine,	   and	   N	   methyl	   O	   glucuronide	   dexmedetomidine,	   which	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accounted	  for	  approximately	  18%	  of	  the	  dose	  in	  urine.	  The	  aliphatic	  hydroxylation	  is	   primarily	  mediated	   through	   CYP	   2A6,	  whereas	   CYP1A2,	   CYP2E1,	   CYP2D6	   and	  CYP2C19	  only	  have	  a	  minor	  role.	  	  	  Due	   to	   the	  extensive	   liver	  metabolism,	  dose	   reductions	   should	  be	   considered	   for	  patients	   with	   liver	   impairment.	   Compared	   to	   healthy	   subjects,	   clearance	   was	  lowered	   by	   53,	   64	   and	   74	   percent	   in	   adults	   with	   mild,	   moderate,	   and	   severe	  hepatic	   dysfunction,	   respectively	   (Product	   monograph:	   Precedex®,	   2016).	   In	  patients	  with	  severe	  renal	  dysfunction	  the	  pharmacokinetics	  of	  dexmedetomidine	  did	  not	  significantly	  change	  compared	  to	  healthy	  subjects.	  	  2.4.3	  Therapeutic	  use	  of	  dexmedetomidine	  	  In	  1999,	  dexmedetomidine	  was	  approved	   for	  human	  use	   in	   the	  USA	  by	   the	  Food	  and	   Drug	   Administration	   (FDA)	   (Approval	   letter:	   Precedex®	   1999).	  Dexmedetomidine	  was	  approved	   to	   the	   ICU	  setting	   for	  sedation	  of	   intubated	  and	  mechanically	  ventilated	  patients.	  The	  indication	  has	  since	  been	  extended	  sedation	  of	   non-­‐intubated	   patients	   prior	   to	   and/or	   during	   surgical	   and	   other	   procedures	  (Hospira	   Press	   Release	   2008).	   In	   September	   2011,	   dexmedetomidine	   was	  approved	  in	  Europe	  by	  the	  European	  Medicine	  Agency	  (EMA)	  (EPAR	  summary	  for	  the	  public:	  Dexdor®	  2011).	  However,	  in	  Europe	  the	  dexmedetomidine	  is	  approved	  for	  sedation	  of	  adult	  patients	  in	  ICUs	  only.	  	  Dexmedetomidine	  is	  currently	  mainly	  used	  in	  the	  ICUs	  and	  in	  surgical	  units	  as	  an	  analgosedative	  (Yu	  2012).	  Compared	  with	  other	  sedatives,	  such	  as	  GABA	  (gamma-­‐aminobutyric	   acid)ergic	   drugs,	   dexmedetomidine	   induced	   sedation	   is	  characterized	   with	   arousability.	   This	   unique	   characteristic	   allows	   the	   medical	  study	   to	   communicate	   with	   the	   patient,	   thus	   improving	   the	   patient’s	   care	   and	  outcome.	  Furthermore,	  dexmedetomidine	  has	  been	  proven	   to	  maintain	   sufficient	  sedation	  without	  respiratory	  depression	  and	  hemodynamic	  instability	  (Siobal	  et	  al.	  2006).	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2.4.4	  Off-­‐label	  therapeutic	  uses	  of	  dexmedetomidine	  	  As	  previously	  mentioned,	  dexmedetomidine	  is	  approved	  only	  for	  ICU-­‐sedation	  and	  in	   USA	   additionally	   for	   sedation	   prior	   to	   and/or	   during	   surgical	   or	   other	  procedures.	   However,	   dexmedetomidine	   has	   been	   shown	   to	   be	   useful	   in	   other	  clinical	  settings	  outside	  the	  approved	  therapeutic	  indications.	  	  Dexmedetomidine	   is	   increasingly	   used	   off-­‐label	   to	   treat	   delirium	   in	   the	   ICU	   as	   a	  recent	   study	   suggested	   dexmedetomidine	   having	   a	   beneficial	   effect	   on	   the	  postoperative	   complication	   delirium	   (McLaughlin	   and	  Marik	   2016).	   Additionally,	  dexmedetomidine	   is	   used	   to	   prevent	   shivering	   during	   spinal	   anesthesia	   after	   a	  study	   demonstrated	   that	   dexmedetomidine	   infusion	   during	   perioperative	   period	  decreased	  the	  shivering	  associated	  with	  the	  spinal	  anesthesia	  (Usta	  et	  al.	  2011).	  	  Dexmedetomidine	   product	   approval	   includes	   only	   adult	   patients.	   However,	  dexmedetomidine	   is	   increasingly	   used	   off-­‐label	   on	   pediatric	   patients.	   Currently	  dexmedetomidine	  has	  been	  administered	  in	  the	  ICU	  for	  sedation	  and	  analgesia	  and	  in	   ambulatory	   anesthesia	   e.g.	   for	   sedation	   during	   non-­‐invasive	   procedures	   in	  radiology	  (Phan	  and	  Nahata	  2008).	  Furthermore,	   it	   is	  also	  used	  for	  postoperative	  delirium	  and	  shivering	  in	  pediatric	  patients.	  	  	  2.5	  Pharmacokinetics	  (PK)	  	  Pharmacokinetics	   is	   the	   study	   of	   the	   time	   course	   of	   a	   drug	   and	   its	   metabolites	  passing	  through	  the	  body.	  During	  the	  passage	  the	  amount	  of	  drug	  changes	  due	  to	  absorption,	   distribution,	  metabolism	  and	  elimination.	  These	   four	  phases	   (ADME)	  influence	  the	  drug	  concentration	  and	  the	  total	  drug	  exposure	  to	  the	  tissue,	  thereby,	  affecting	  the	  pharmacological	  activity	  of	  the	  drug	  in	  the	  body.	  Hence,	  it	  is	  crucial	  to	  determine	  the	  biological	  fate	  of	  the	  drug.	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To	  describe	  and	  predict	  pharmacokinetic	  parameters,	  such	  as	  bioavailability,	  area	  under	  the	  plasma	  concentration-­‐time	  curve	  (AUC),	  clearance,	  and	  elimination	  half-­‐life	   are	   calculated	   and	  used	   in	   pharmacokinetic	   studies.	   Bioavailability	   describes	  the	   fraction	  or	  percentage	  of	   the	  given	  drug	  that	  has	  been	  absorbed	  to	   the	  blood	  circulation	  after	  an	  extravascular	  (EV)	  dose,	  AUC	  is	  the	  total	  systemic	  exposure	  to	  the	  drug,	  clearance	  the	  volume	  of	   the	  drug	  being	  eliminated	  per	  unit	  of	   time	  and	  elimination	   half-­‐life	   is	   the	   time	   it	   takes	   to	   eliminate	   half	   of	   the	   dose.	   Additional	  parameters,	   for	   example,	   the	   maximum	   concentration	   (Cmax)	   and	   the	   time	   at	  maximum	  concentration	  (Tmax),	  are	  also	  determined	  in	  pharmacokinetic	  analyses.	  	  	  2.6	  PK-­‐analysis	  methods	  	  2.6.1	  NCA	  	  and	  compartmental	  methods	  	  Both	  non-­‐compartmental	   analysis	   (NCA)	   and	   compartmental	  modeling	  belong	   to	  the	   classical	   PK	   analyses	   (Sherwin	   et	  al.	   2014).	   The	   statistical	  moments	   derived	  from	   the	   time	   course	   of	   the	   drug	   concentration	   data	   are	   the	   foundation	   for	   the	  NCA,	   whereas	   compartmental	   modeling	   is	   being	   based	   on	   the	   mass	   balance	  equations	  of	  the	  compartments.	  	  NCA	   is	   used	   to	   obtain	   pharmacokinetic	   parameters	   without	   using	   a	   specific	  compartment	  model	   (Gabrielsson	   and	  Weiner	   2012).	   The	   total	   drug	   exposure	   is	  determined	   from	   the	  AUC,	  which	   in	  NCA	   is	   usually	   calculated	  by	   the	   trapezoidal	  rule	   (Gabrielsson	   and	  Weiner	   2012).	   	   In	   the	   trapezoidal	   rule	   the	  measured	   data	  points	  are	  used	  to	  split	  the	  curve	  into	  a	  series	  of	  segments,	  thus	  forming	  trapezoids	  except	   the	   first,	   which	   forms	   a	   triangle	   (Figure	   6).	   All	   following	   equations	   are	  based	  on	  Gabrielsson	  and	  Weiner	  2012.	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Figure 6. The measured plasma concentration points split the curve in to segments 
forming trapezoids, except for the first forming a triangle. 	  The	  area	  of	  a	  segment	  is	  calculated	  by	  the	  use	  of	  the	  equation:	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝐴𝑟𝑒𝑎 = !!!!!!!!!! ×(𝑡!!! − 𝑡!),	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1)	  	  where	  the	  Cpn	  is	  the	  plasma	  concentration	  in	  the	  nth	  time	  point	  trapezoid,	  Cpn+1	  is	  the	  plasma	  concentration	  in	  the	  following	  time	  point	  trapezoid,	  tn+1	  the	  time	  at	  the	  n+1	  time	  point	  trapezoid,	  and	  tn	  the	  time	  at	  the	  nth	  time	  point	  trapezoid.	  However,	  the	  area	  for	  the	  last	  segment,	  last	  concentration	  time-­‐point	  to	  infinity,	  is	  calculated	  by	  dividing	  the	  concentration	  at	  that	  time-­‐point	  with	  the	  elimination	  rate	  constant.	  The	  areas	  of	  all	  the	  segments	  are	  then	  summarized	  to	  obtain	  the	  AUC.	  	  After	  AUC	  has	  been	  estimated,	  both	  clearance	   (CL)	  and	  bioavailability	   (F)	   can	  be	  calculated.	   To	   calculate	   percentage	   bioavailability	   (F%)	   AUC	   for	   both	   IV	   and	  extravascular	  (EV)	  doses	  ought	  to	  be	  calculated.	  	  The	  following	  equation	  is	  used:	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝐹% = 100  ×   !"#!"!"#!" × !!"!!"	  ,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2)	  	  where	   	  AUCev	  and	  AUCiv	  are	   the	  AUC	   from	  the	  EV	  dose	  and	   IV	  dose,	   respectively,	  and	  Div	  and	  Dev	  are	  the	  given	  IV	  and	  EV	  dose,	  respectively.	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The	   IV	   clearance	   is	   calculated	   by	   dividing	   the	   given	   dose	  with	   AUC0-­‐∞	   as	   in	   the	  following	  equation:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝐶𝐿 = !"#$!"!"!!!!	  ,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3)	  	  When	   IV	   data	   is	   not	   available	   the	   apparent	   extravascular	   clearance	   (CL/F)	   is	  obtained	  by	  dividing	  the	  extravascular	  (EV)	  dose	  with	  the	  extravascular	  AUC0-­‐∞	  as	  can	  be	  seen	  in	  the	  following	  equation:	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝐶𝐿/𝐹 = !"#$!"!"#!!!	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (4)	  	  The	   elimination	   half-­‐life	   is	   obtained	   by	   dividing	   the	   constant	   0.693	   with	   the	  elimination	  rate	  constant,	  ke,	  as	  in	  the	  following	  equation:	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  t  !/! = !.!"#!! 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (5)	  	  To	   obtain	   the	  Cmax	   and	  Tmax	  no	   equations	   are	  needed,	   since	  both	   values	   are	   read	  from	  the	  concentration	  time	  data.	  	  	  In	   the	   PK	   compartment	   model	   analysis	   models	   are	   used	   to	   describe	   the	   time-­‐course	   of	   drug	   exposure	   after	   administration	   of	   different	   doses,	   and	   to	   give	  estimates	   for	   pharmacokinetic	   parameters	   such	   as	   clearance	   and	   volume	   of	  distribution	   (Mould	   and	  Upton	  2012).	  PK	  models	   are	  based	  on	   simple	   structural	  compartments,	   for	   example,	   the	   central	   compartment,	   peripheral	   compartment,	  and	  elimination	  compartment,	  which	  are	  then	  connected	  to	  each	  other	  with	  first-­‐order	   processes.	   These	   parameters	   may	   be	   used	   to	   simulate	   the	   drug	  concentration	  obtained	  by	  a	  given	  dose	  in	  different	  compartments	  during	  a	  given	  time	   interval.	   Therefore,	   one	   can	   obtain	   the	   estimated	   drug	   concentration	   in	  plasma	   at	   a	   given	   time,	   the	   concentration	   eliminated	   at	   a	   given	   time	   and	   other	  valuable	  information	  after	  administration	  of	  a	  given	  amount	  of	  the	  drug.	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  As	  can	  be	  seen	   in	  Figure	  7,	  describing	  the	  drug	  transport	   from	  the	  apical-­‐	   to	   the	  basolateral	   side	   of	   the	   lumen,	   the	   model	   consist	   of	   compartments	   representing	  given	   physical	   entities,	   which	   are	   connected	   to	   each	   other	   by	   mathematical	  formulas	  or	  given	  parameter	  values	  to	  be	  able	  to	  simulate	  the	  drug	  movement.	  The	  construction	  is	  very	  simple	  and	  it	  gives	  a	  good	  understanding	  of	  the	  time	  course	  of	  the	  drug	  exposure	  in	  the	  basolateral	  side	  of	  the	  lumen.	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 7. PK model in Stella software simulating paracetamol transport from the apical- 
to the basolateral side in lumen. Apical and basolateral boxes represent the apical and 
basolateral side of the lumen. The circles represent parameters, such as permeability 
(Papp), area of the lumen (area), concentration in the apical side (C1), the volume in the 
apical- and basolateral side (volume apical/volume baso), which through mathematical 
formulas aid to obtain the concentration of paracetamol (C2) in the basolateral 
compartment at given time points. 	  In	  a	  PK	  model	  the	  compartments	  are	  typically	  abstract	  concepts	  not	  automatically	  representing	   a	   particular	   region	   of	   the	   body	   (Mould	   and	   Upton	   2012).	   Hence,	  physiology-­‐based	  PK	  models	   (PBPK)	  are	  being	  used	   to	  represent	  given	  organs	  of	  the	   body,	   which	   then	   are	   connected	   by	   the	   vascular	   system	   according	   to	   the	  anatomic	  structure	  (Nestorov	  2007).	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2.6.2	  Pharmacometrics	  	  Pharmacometrics	   is	   a	   science	   branch	   involving	   mathematical	   models	   of	  pharmacology,	   disease,	   biology	   and	   physiology	   for	   describing	   and	   quantifying	  interactions,	   both	   beneficial-­‐	   and	   side	   effects,	   between	   xenobiotics	   and	   patients	  (Barrett	   et	   al.	   2009).	   In	   the	   beginning	   pharmacometrics	   was	   described	   as	   the	  methodology	   for	   evaluating	   population	   based	   data,	   especially	   population	  pharmacokinetics	   (Williams	   and	   Ette	   2007).	   Nowadays	   it	   has	   a	   much	   broader	  definition,	   since	   the	   term	   pharmacometrics	   has	   become	   the	   overall	   term	   for	  describing	  modeling	  and	  simulation	  for	  PK,	  exposure-­‐response	  relationships,	  and	  disease	  progression	  (Sherwin	  et	  al.	  2014).	  	  Pharmacometrics	   uses	   data	   from	   animals,	   healthy	   subjects	   and	   patients	   to	  understand	   the	   drug	   behavior,	   disease	   progression	   and	   its	   effect	   on	   individual	  patients	   (Sherwin	   et	   al.	   2014).	   Additionally,	   pharmacometrics	   is	   utilized	   to	  personalize	  medicine	  to	  specific	  groups	  of	  patient	  population,	  thereby,	   improving	  the	  efficacy	  and	  minimizing	  toxicity	  of	  the	  drug.	  	  	  Pharmacometrics	  has	  become	  an	  important	  tool	  in	  drug	  development.	  It	  combines	  data,	   knowledge,	   and	  mechanisms	   to	   help	   make	   reasonable	   decisions	   regarding	  drug	   use	   and	   development	   (Mould	   and	   Upton	   2012).	   The	   models	   are	  representations	   of	   the	   system	  being	   evaluated.	   The	  models	   are	   highly	   simplified	  representations,	   however,	   it	   is	   the	   simplification	   that	   makes	   them	   useful.	   Thus,	  depending	  on	   the	  aim	  of	   the	   study	   the	  best	   fitted	  model	   is	  being	  used.	   Since	   the	  most	  important	  factor	  is	  how	  well	  the	  model	  describes	  the	  phenomena,	  not	  if	  the	  model	  is	  right	  or	  true.	  	  	  2.6.3	  Basics	  of	  population	  PK	  	  A	  drug	   exhibits	   variability	   in	   exposure	  between	  patients	   leading	   to	   variability	   in	  the	   clinical	   response	   across	   the	   population	   (Weber	   and	   Rüppel	   2013	   originated	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from	  Rowland	  et	  al.	  1985).	  To	  be	  able	  to	  estimate	  the	  PK	  variability	  across	  patients	  large	   data	   is	   required,	   typically	   more	   than	   100	   patients.	   Traditionally	   the	  population	  parameters	  have	  been	   estimated	  by	   the	   “two-­‐stage	   approach”,	  where	  the	   individuals’	   data	   were	   first	   fitted	   separately.	   Then	   mean	   population	  parameters	   were	   calculated	   summing	   up	   the	   individual	   parameter	   estimates.	  Another	  method,	  called	  “naïve	  pool	  approach”,	  fits	  all	  individual	  data	  together	  like	  there	   were	   no	   individual	   kinetic	   differences	   (Sheiner	   and	   Beal	   1980).	   In	   1977,	  Sheiner	  and	  co-­‐workers	  suggested	  a	  method	  for	  investigating	  the	  PK	  of	  a	  drug	  in	  a	  population	  (Weber	  and	  Rüppel	  2013).	  The	  method	  does	  not	  need	  a	  large	  data	  set,	  instead	  sparse	  and	  unbalanced	  data	  can	  be	  used	  to	  investigate	  the	  typical	  PK	  of	  a	  drug.	  Hence,	  parameter	  estimates	  can	  be	  obtained	  for	  individuals	  for	  whom	  there	  are	  too	  few	  observations	  for	  standard	  parameter	  estimation	  methods	  (Mould	  and	  Upton	   2012).	   Various	   settings	   can	   be	   modeled	   with	   pharmacometric	   methods,	  such	   as	   a	   “sparse”	   data	  with	   as	   little	   as	   one	   observation	   per	   subject,	   “rich”	   data	  with	   many	   observations	   per	   subject	   or	   a	   combination	   of	   both,	   where	   many	  samples	   are	   collected	   for	   some	   subjects	   and	   only	   a	   few	   samples	   for	   the	   others	  (Bonate	  2011).	  	  	  The	   population	   PK	   is	   based	   on	   nonlinear	   mixed	   effect	   modeling	   (Sherwin	   et	   al.	  2014),	  which	   is	   used	   to	  model	   and	   identify	   variability	   in	   drug	   concentrations	   or	  pharmacological	  effects	  between	   individuals	   (Mould	  and	  Upton	  2012:	  Mould	  and	  Upton	   2013).	   It	   uses	   the	   structural	   simplicity	   of	   the	   classical	   compartment	   PK	  models	  but	  manages	  to	  associate	  the	  PK	  parameters	  to	  different	  covariates	  such	  as	  age,	   gender,	   body	   weight	   etc.	   (Sherwin	   et.	   al.	   2014).	   All	   of	   these	   physiological	  factors	  affect	   the	  exposure	  of	  a	  drug	   (Mould	  and	  Upton	  2012),	   for	  example,	  both	  clearance	   and	   volume	   of	   distribution	   is	   affected	   by	   body	  weight	   (Sherwin	   et.	   al.	  2014).	  These	  factors	  vary	  between	  subjects,	  generating	  variation	  in	  drug	  exposure	  (Mould	  and	  Upton	  2012).	  Therefore,	  it	  is	  of	  great	  interest	  to	  identify	  and	  quantify	  the	   intra-­‐	   and	   inter-­‐individual	   variability	   for	   a	   given	   drug.	   Additionally,	   the	  population	   model	   is	   useful	   for	   rationalizing	   drug	   development	   and	   to	   establish	  optimal	   dosing	   strategies	   for	   specific	   patient	   groups,	  which	   cannot	   otherwise	   be	  studied	  (e.g.	  intensive	  care	  patients	  and	  infants	  (Struys	  et	  al.	  2011).	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Pharmacometric	   models	   are	   used	   to	   simultaneously	   evaluate	   the	   data	   from	   all	  individuals	  in	  a	  population	  (Bonate	  2011).	  The	  data	  is	  associated	  with	  a	  nonlinear	  mixed	   effect	   model,	   using	   repeated	   measures	   trial	   design	   (Aarons	   2014).	   The	  computer	  software	  (NONMEM,	  Icon	  Software)	   implementing	  the	  nonlinear	  mixed	  effect	  model	  is	  written	  in	  FORTRAN	  and	  was	  developed	  by	  Beal	  and	  Sheiner	  (Beal	  and	  Sheiner	  1980).	  	  	  2.7	  Components	  of	  the	  population	  PK	  model	  	  In	  nonlinear	  mixed	  effects	  modeling,	  as	  the	  name	  “nonlinear”	  implies,	  the	  function	  under	   consideration	   is	   nonlinear	   to	   the	   model	   parameter,	   more	   precisely	   the	  dependent	   variable	   is	   nonlinearly	   related	   to	   the	   model	   parameters	   and	  independent	   variables	   (Bonate	   2011).	   The	  model	   incorporates	   both	   fixed	   effects	  and	  random	  effects,	  hence	  the	  name	  mixed	  effects	  modeling.	  The	  fixed	  effect	  model	  incorporates	   the	   individual	   pharmacokinetic	   parameters,	   identified	   covariates,	  thereby,	   the	   known	   sources	   of	   inter-­‐individual	   variability	   (Sherwin	   et.	   al.	  2014).	  The	   random	   effects,	   on	   the	   other	   hand,	   include	   the	   unidentified	   sources	   of	  variability.	   In	   the	   nonlinear	   mixed	   effects	   model	   one	   achieves	   to	   model	   the	  correlation	  between	  a	  set	  of	   independent	  variables	  and	  some	  dependent	  variable	  (Bonate	   2011).	   The	   dependent	   variable	   is	   concentration	   and	   the	   independent	  variables	  are	  dose,	  time	  and	  possibly	  covariates	  like	  weight	  and	  age.	  The	  structure	  of	  a	  population	  mixed	  effects	  model	  is	  thus:	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑌!! = 𝑓 𝑥!" ,𝜃, 𝜂! + 𝜀! 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (6)	  where	  the	  jth	  estimated	  drug	  concentration	  for	  an	  individual	  i	  (𝑌!")	  is	  a	  function	  of:	  a	   vector	   of	   pharmacokinetic	   parameters	   (𝜃),	   individual	   characteristics	   (fixed	  effects,	  𝑥!" ),	   inter-­‐individual	   or	   between	   subject	   variability	   (IIV	   or	   BSV)	   and	  random	  effects	  described	  by	  residual	  error	  (𝜀!).	  However,	  nonlinear	  mixed	  effects	  modeling	   can	   be	   used	   to	  model	   and	   simulate	   various	   dependent	   variables	   from	  pharmacodynamic	  studies	  and	  clinical	  trials.	  
29	  	  
	  
The	   nonlinear	   mixed	   effects	   model	   is	   composed	   of	   structural-­‐,	   statistical-­‐,	   and	  covariate	   models	   (Figure	   8)	   (Mould	   and	   Upton	   2013).	   The	   structural	   models	  describe	   the	   concentration	   time	   course	   within	   the	   population,	   whereas	   the	  statistical	  models	  clarify	   the	  unaccountable	  random	  effects	  within	  the	  population	  (Bonate	   2011).	   The	   covariate	   models	   stand	   for	   the	   variability	   due	   to	   subject	  physiologic	   characteristics	   (covariates).	   These	   models	   and	   the	   data	   are	   then	  brought	   together	   by	   the	   nonlinear	  mixed	   effects	  modeling	   software	   (NONMEM).	  Thereby,	  giving	  parameters	   to	   the	  describing	  structural,	   statistical,	   and	  covariate	  models.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	   8.	   Principles	   of	   population	   modeling.	   A.	   Population	   models	   consist	   of	  several	   components:	   structural	  models,	   statistical	  models,	   and	   covariate	  models.	  Functions	   that	   describe	   the	   time	   course	   of	   a	   measured	   response	   (e.g.	  concentrations)	  build	  of	   the	  structural	  model.	  The	  statistical	  model	  describes	   the	  variability	   in	   the	   observed	   data,	   whereas	   the	   covariate	   model	   describes	   the	  influence	  of	  physical	  factors	  such	  as	  weight,	  height,	  age	  etc.	  on	  the	  individual	  time	  course	  of	  the	  response.	  B.	  A	  pharmacokinetic	  study	  with	  two	  subjects	  (red	  lines),	  where	   each	   subject	   has	   received	   a	   single	   intravenous	   dose.	   Fixed	   and	   random-­‐effect	   parameters	   are	   both	   included	   in	   population	   modeling	   and	   are,	   therefore,	  called	  “mixed-­‐effect”	  models.	  	  The	  structural	  model	  (blue	  line)	  represents	  the	  fixed	  effects	   by	   parameters	   that	   have	   the	   same	   value	   for	   every	   subject	   (θPOP).	   Each	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subject	  (i)	  is	  then	  described	  by	  individual	  parameter	  values	  (yi),	  and	  can	  be	  seen	  as	  red	   lines.	   The	   difference	   between	   an	   individual’s	   parameter	   value	   and	   the	  population	  value	  is	  accounted	  by	  the	  random	  effects	  (ηi).	  The	  difference	  between	  the	   observed	   data	   for	   an	   individual	   (Cij)	   and	   the	   model’s	   prediction	   for	   each	  measurement	  (j)	  is	  described	  by	  residual	  or	  unexplained	  error	  (εij).	  C.	  To	  describe	  the	   pharmacokinetics	   a	   one-­‐compartment	   model	   is	   used.	   The	   covariate	   model	  indicates	  that	  clearance	  (CLPOP)	  scales	  linearly	  with	  body	  weight	  (WT),	  thereby,	  the	  variability	   in	   this	   parameter	   can	   be	   described	   by	   covariate,	   body	   size.	   The	  statistical	  model	   incorporates	   the	   influence	  of	   residual	  error	  and	  random	  effects.	  To	   calculate	   the	   population	   (CPRED)	   and	   individual	   (CIPRED)	   predicted	  concentrations	  the	  model	  equations	  are	  used.	  Population	  models	  can	  be	  employed	  to	  simulate	  scenarios	  after	  clinically	  relevant	  dosing	  schemes.	  Figure	  D	  shows	  the	  effect	  of	  age	  on	  simulated	  concentration-­‐time	  course	  of	  oxycodone	  after	   IV	  bolus	  dosing.	  Adapted	  from	  Olkkola	  et	  al.	  2013	  	  	  2.7.1	  Structural	  model	  	  A	  structural	  model	  is	  equivalent	  to	  systemic	  models	  and	  absorption	  models,	  which	  are	  models	  describing	  the	  kinetics	  after	  IV	  dosing	  and	  drug	  uptake	  into	  the	  blood	  circulation	  after	  extravascular	  dosing,	   respectively	   (Mould	  and	  Upton	  2013).	  The	  structural	  model	  may	   consist	   of	   one,	   or	   several	   compartments	  depending	  on	   the	  number	  of	  exponential	  phases	  obtained	  by	  plotting	  concentration	  versus	  time.	  To	  estimate	  the	  amount	  of	  compartments	  needed	  in	  the	  structural	  model	  one	  can	  plot	  log	   concentration	   versus	   time,	   as	   each	   distinct	   declining	   linear	   phase	   generally	  demands	   its	   own	   compartment.	   It	   is	   of	   great	   importance	   to	   choose	   the	   right	  number	  of	  compartments	  in	  the	  structural	  model,	  because	  too	  few	  compartments	  will	   describe	   the	   data	   poorly,	   giving	   a	   higher	   OFV	   (objective	   function	   value),	  whereas	   too	  many	  compartments	  will	  show	  improvement	   in	  OFV,	  poor	  precision	  in	   parameter	   estimation	   and	   the	   additional	   peripheral	   compartment	   parameters	  will	  converge	  on	  values	  that	  have	  minimal	  influence	  on	  the	  plasma	  concentrations	  (Mould	  and	  Upton	  2013).	  OFV	  describes	  how	  well	  the	  model	  predictions	  match	  the	  data,	  the	  lowest	  OFV	  equals	  the	  best	  fit.	  	  The	  order	  of	  the	  elimination	  needs	  to	  be	  taken	  in	  consideration	  when	  the	  model	  is	  being	   developed	   (Mould	   and	   Upton	   2012).	   When	   the	   drug	   exhibits	   first-­‐order	  elimination	  the	  rate	  of	  elimination	  is	  proportional	  to	  concentration	  and	  clearance	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is	   constant.	   In	   zero-­‐order	   elimination	   systems	   the	   rate	   of	   elimination	   is	  independent	   of	   concentration	   and	   clearance	   depends	   on	   the	   dose	   administered.	  Generally,	  as	  the	  concentration	  increase	  the	  elimination	  moves	  progressively	  from	  first-­‐order	  elimination	  to	  zero-­‐order	  elimination,	  thereby,	  showing	  a	  saturation	  of	  the	  elimination	  pathways.	  	  However,	  pharmacokinetic	  data	  collected	  from	  subjects	  receiving	   a	   single	   dose	   are	   seldom	   sufficient	   to	   quantify	   and	   confirm	   saturable	  elimination,	  but	  several	  doses	  may	  be	  needed.	  	  When	  a	  drug	  is	  given	  through	  extravascular	  routes	  it	  exhibits	  an	  absorption	  phase,	  which	   ought	   to	   be	   taken	   into	   consideration.	   Therefore,	   a	   structural	   model	  component	   representing	   absorption	   is	  needed,	  where	   two	   factors,	   bioavailability	  and	   absorption	   rates,	   are	   the	   key	   processes	   affecting	   the	   total	   concentration	  (Mould	  and	  Upton	  2013).	  Total	  bioavailability	  can	  only	  be	  calculated	  when	  both	  IV	  and	  extravascular	  data	  are	  available.	  The	  amount	  of	  unabsorbed	  drug	  depend	  on	  the	  route	  of	  administration	  and	  the	  drug,	  for	  example,	  the	  drug	  does	  not	  penetrate	  the	   gastrointestinal	   wall,	   is	   metabolized	   during	   absorption	   or	   precipitates	   or	  aggregates	  at	  the	  injection	  site.	  	  Secondly,	  which	  earlier	  mentioned,	  is	  the	  effect	  of	  the	  absorption	  rate	  on	  the	  total	  concentration.	   	   Most	   extravascular	   administered	   drugs	   exhibit	   an	   absorption	  process,	   called	   first-­‐order	   absorption,	  which	   is	   described	   by	   the	   absorption	   rate	  constant	  ka	  (Mould	  and	  Upton	  2013).	  This	  absorption	  rate	  constant	  represents	  the	  absorption	   as	   a	   passive	   process,	   which	   is	   driven	   by	   the	   concentration	   gradient	  between	   the	   absorption	   site	   and	   blood.	   Thereby,	   resulting	   in	   a	   descending	  concentration	   gradient	   with	   time	   as	   the	   drug,	   in	   an	   exponential	   manner,	   is	  depleted	  at	  the	  absorption	  site.	  In	  cases	  where	  the	  drug	  in	  the	  blood	  is	  delayed,	  a	  lag	   time	   in	   the	   absorption	   may	   be	   added	   to	   the	   model.	   However,	   some	   drugs	  exhibit	  zero-­‐order	  absorption,	  as	  in	  drug	  elimination,	  where	  the	  drug	  is	  absorbed	  with	  constant	  rate.	  This	   is	  due	  to	  either	  a	  saturable	  absorption	  process	  or	  where	  the	  release	  of	  the	  drug	  in	  the	  drug	  reservoir	  is	  constant.	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2.7.2	  Statistical	  model	  	  To	  describe	  the	  variability	  associated	  with	  the	  structural	  model	  a	  statistical	  model	  is	   being	   used	   (Mould	   and	   Upton	   2013).	   In	   population	   pharmacokinetic	   models	  there	  are	  two	  principal	  sources	  of	  variability:	   inter-­‐individual	  or	  between	  subject	  variability	   (BSV)	   and	   the	   residual	   variability	   (RUV).	   BSV	   is	   the	   variance	   of	   a	  parameters	   across	   individuals,	   whereas	   RUV	   is	   the	   unexplained	   variability	   after	  other	  sources	  of	  variability	  have	  been	  excluded.	  	  The	   parameter	   values	   from	   the	   structural	   model	   typically	   exhibit	   variability	  between	   every	   subject.	   In	   the	   statistical	   model	   the	   BSV	   is	   described	   by	  parametrization,	  which	  is	  mostly	  based	  on	  the	  type	  of	  data	  being	  evaluated	  (Mould	  and	   Upton	   2013).	   In	   the	   structural	   model,	   a	   population	   value	   described	   by	   the	  Greek	  letter	  θ,	  is	  obtained	  for	  a	  given	  pharmacokinetic	  parameter.	  To	  describe	  the	  deviation	  from	  the	  population	  value	  for	  a	  given	  subject	  the	  Greek	  letter	  η	  is	  being	  used.	  The	  description	  of	  BSV	  can	  be	  done	  by	  using	  the	  additive	  function:	  θ	  =	   	  θ1+	  η1i,	   where	   θ1	  is	   the	   population	   value	   and	   η1i	   is	   the	   deviation	   for	   the	   ith	   subject.	  However,	  the	  assumption	  that	  η	  values	  are	  normally	  distributed	  with	  a	  mean	  of	  0	  and	  variance	  ω2	   is	  not	  always	  correct.	  Therefore,	  when	  η	  values	  have	  skewed	  or	  kurtotic	  distribution	  transformation	  is	  necessary	  to	  obtain	  normal	  distribution	  of	  η	  values.	   Log-­‐normal	   distribution	   is	   often	   assumed	   in	   pharmacokinetics	   because	  parameters	  must	  be	  positive	  and	  often	  right-­‐skewed	  (Lacey	  et	  al.	  1997:	  Limpert	  et	  
al.2001).	  In	  a	  log-­‐normal	  distribution	  a	  parameter	  value,	  e.g.	  clearance	  for	  a	  given	  subject,	  CLi,	   can	  be	  described	  with	   the	   function:	  Cli=	  θ1	  *	  exp(n1i),	  where	  θ1	  is	   the	  population	   clearance	   and	   n1i	   	   is	   the	   deviation	   from	   the	   population	   for	   the	   ith	  subject	  (Mould	  and	  Upton	  2013).	  	  	  Assay	  variability,	  errors	  in	  sample	  time	  collection,	  and	  model	  misspecification	  are	  sources	   creating	   residual	   variability	   in	   the	   population	   (Mould	   and	   Upton	   2013).	  The	   residual	   variability	   is	   described	   by	   the	  Greek	   letter	   ε.	   Analogous	   to	  BSV	   the	  type	   of	   data	   being	   evaluated	   determines	   the	   selection	   of	   RUV	   model.	   Several	  functions,	  for	  example	  additive,	  proportional	  and	  a	  combination	  of	  both,	  are	  being	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used	   to	  describe	  RUV.	  The	  combined	  additive	  and	  proportional	  error	  models	  are	  often	  utilized	  in	  dense	  pharmacokinetic	  data,	  whereas	  in	  pharmadynamic	  data	  the	  additive	  error	  model	   is	  suitable.	  The	  additive	  formula	  is	  expressed	  as	  follows:	  Y=	  f(θ,	   Time)	   +	   ε,	   where	   f	   (θ,	   Time)	   is	   the	   function	   describing	   the	   time-­‐dependent	  behavior	   of	   pharmacokinetic	   parameters	   (THETA).	   As	   with	   the	   BSV	   models	   the	  term	  describing	  RUV,	   ε,	   is	  assumed	   to	  be	  normally	  distributed,	   independent,	   and	  with	  a	  mean	  of	  0	   and	  a	  variance	  σ2.	  Notwithstanding,	   the	  assumption	  of	  η	   and	   ε	  being	  independent	  is	  often	  incorrect,	  which	  for	  example	  can	  clearly	  be	  seen	  in	  the	  proportional	  error	  model;	  Y=	  f	  (θ,	  η,	  Time)	  x	  (1+ε).	  However,	  this	   interaction	  can	  be	   accounted	   for	   in	   the	   likelihood	   estimation.	   When	   the	   RUV	   is	   not	   normally	  distributed,	   but	   kurtotic	   or	   right-­‐skewed,	   transformation	   is	   necessary,	   similar	   to	  BSV.	  	  2.7.3	  Covariate	  model	  	  A	   covariate	   model	   explains	   the	   predicted	   variability	   (Mould	   and	   Upton	   2013).	  These	   predicted	   variabilities	   are	   important	   to	   identify	   in	   population	  pharmacokinetic	  evaluations.	  The	  first	  step	  is	  to	  select	  potential	  covariates,	  which	  is	   usually	   based	   on	   known	  properties	   of	   the	   drug,	   drug	   class,	   or	   physiology.	   For	  example,	   when	   a	   drug	   is	   highly	   metabolized,	   covariates	   such	   as	   weight,	   liver	  enzymes,	  and	  genotype	  will	  be	  included.	  The	  next	  step	  is	  to	  preliminarily	  evaluate	  the	  selected	  covariates.	  However,	  the	  run	  times	  can	  occasionally	  be	  extensive	  and,	  therefore,	   it	   is	  often	  necessary	  to	   limit	   the	  number	  of	  covariates	  evaluated	   in	   the	  model.	  Different	  covariate	  screening	  methods	  aid	  in	  determining	  the	  importance	  of	  selected	  covariates	  and,	  thereby,	  reduces	  the	  number	  of	  evaluations.	  The	  final	  step	  is	  to	  build	  the	  covariate	  model.	  If	  covariate	  screening	  has	  been	  conducted	  only	  the	  covariates	   identified	   in	   the	   screening	   are	   evaluated	   separately	   and	   the	   relevant	  covariates	   are	   included.	   However,	   if	   covariate	   screening	   was	   not	   conducted,	   all	  covariates	  are	  tested	  separately	  and	  those	  covariates	  meeting	  the	  inclusion	  criteria	  are	  counted.	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The	  covariates	  can	  either	  be	  continuous	  or	  discrete	  (Mould	  and	  Upton	  2012).	  The	  continuous	   covariates	   have	   values	  which	   are	   uninterrupted,	   for	   example	  weight,	  whereas	   discrete	   values	   are	   distinct	   classes	   or	   unconnected	   values,	   for	   example	  sex.	   These	   two	   classes	   of	   covariates	   are	   handled	   differently.	   The	   effect	   of	  continuous	  covariates	  can	  be	  included	  in	  the	  population	  model	  by	  using	  a	  variety	  of	   functions,	   such	  as,	   linear,	  power,	  or	  exponential	   function.	  CL=	   (θ1+	   (Weight)	  x	  θ2)	  x	  exp(n1)	  is	  a	  linear	  function	  and	  describes	  the	  effect	  of	  the	  covariate,	  weight,	  on	   CL.	   The	   discrete	   covariates	   can	   either	   be;	   dichotomous,	   taking	   one	   of	   two	  possible	  values	  such	  as	  sex;	  or	  polychotomous,	  taking	  on	  of	  several	  possible	  values	  such	   as	   race.	   The	   dichotomous	   covariates	   are	   set	   to	   0	   for	   the	   reference	  classification	  and	  1	  for	  the	  other	  classification,	  whereas	  polychotomous	  covariates	  can	  be	  classified	  using	  different	   factors	   for	  each	  classification	  against	  a	  reference	  value	   or	   be	   grouped	   into	   two	   categories.	   When	   the	   covariates	   are	   of	   inherent	  order,	   for	   example,	   the	   degree	   of	   kidney	   failure	   is	   defined	   as	   mild,	   moderate,	  severe	  and	  very	  severe	  (CKD	  stages:	  The	  renal	  association),	  they	  can	  be	  described	  as	  mild=0	  and	  very	  severe=4.	  	  	  2.8	  Previous	  population	  PK	  modeling	  of	  IV	  dexmedetomidine	  	  Population	   pharmacokinetics	   of	   IV	   dexmedetomidine	   has	   previously	   been	  described	  in	  several	  studies.	  The	  first	  study	  was	  conducted	  by	  Dyck	  et	  al.	  (1993ab)	  in	  healthy	  males,	  and	  the	  most	  recent	  model	  was	  published	  last	  year	  (Kuang	  et	  al.	  2016).	   Different	   covariates	   have	   been	   tested,	   and	   both	   healthy	   volunteers	   and	  patients	  have	  been	  studied.	   	  An	  overview	  of	   the	  previously	  published	  population	  pharmacokinetic	  models	  of	  IV	  dexmedetomidine	  is	  shown	  in	  Table	  3.	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Table	  3.	  .	  An	  overview	  of	  the	  previous	  published	  population	  pharmacokinetics	  of	  IV	  dexmedetomidine.	   ALB=albumin,	   ALT=alanine	   transaminase,	   AST	   aspartate	  transaminase,	  BMI=	  body	  mass	  index,	  BSA=	  body	  surface	  area,	  CL=	  clearance,	  CO=	  cardiac	   putout,	   FAT=	   fat	   mass,	   FFM=	   fat-­‐free	   mass,	   HGT=	   height,	   HV=	   healthy	  volunteers,	  LBM=lean	  body	  mass,	  N=number	  of	  subjects,	  CL2=inter-­‐compartmental	  clearance,	  V=	  apparent	  volume	  of	  distribution,	  WGT=	  weight	  	  	  
Study	  
(year)	  









al.(1993a)	  plus	  data	  from	  1993b	  
Male	  HV	  N:10	  (from	  study	  1993b)+6	  	  
31.5	  years	  (27-­‐40)	  82	  kg	  (71-­‐98)	  
Age,	  WGT,	  HGT	   3-­‐compartment,	  with	  HGT	  as	  the	  covariate	  on	  CL	  Talke	  et	  al.	  (1997)	   Female	  postoperative	  patients	  	  N:8	  
36	  years	  (23-­‐44)	  69	  kg	  (62-­‐79)	  166	  cm	  (157-­‐178)	  
Age,	  WGT,	  HGT	   2-­‐compartment	  model	  with	  no	  significant	  influence	  of	  tested	  covariates	  Dutta	  et	  al.	  (2000)	   Male	  HV	  N:	  10	   24	  years	  	  (20-­‐27)	  78	  kg	  (68-­‐89)	  177	  cm	  (170-­‐185)	  
CO	   2-­‐compartment	  model	  with	  CO	  as	  a	  covariate	  on	  CL	  Venn	  et	  al.	  (2002)	   Postoperative	  ICU	  patients	  N:	  10	  
68	  years	  (35-­‐80)	   -­‐	   2-­‐compartment	  model	  with	  no	  tested	  covariates	  reported	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Lin	  et	  al.	  (2011)	   Chinese	  postoperative	  patients	  N:22	  
46	  years	  	  (22-­‐69)	  60	  kg	  (46-­‐78)	  165	  cm	  	  (155-­‐178)	  
Age,	  WGT,	  HGT,	  sex,	  BSA,	  BMI,	  LBM	  
3-­‐compartment	  model	  with	  HGT	  as	  a	  covariate	  on	  CL	  Iirola	  et	  al.	  (2012)	   ICU	  patients	  N:21	   60	  years	  	  (22-­‐85)	  85	  kg	  	  (53-­‐120)	  174	  cm	  (160-­‐181)	  ALB:	  13.5	  (6.6-­‐30.5)	  	  
Age,	  WGT,	  HGY,	  sex,	  BMI,	  LBM	  
2-­‐compartment	  model	  with	  age	  as	  a	  covariate	  on	  CL	  and	  ALB	  on	  V2	  
Lee	  et	  al.	  (2012)	   Korean	  HV	  N:	  24	   27	  years	  71	  kg	  174	  cm	  
Age,	  WGT,	  HGT,	  serum	  creatinine,	  AST,	  ALT,	  ALB	  
2-­‐compartment	  model	  with	  ALB	  as	  a	  covariate	  on	  CL	  and	  age	  on	  V1	  Välitalo	  et	  al.	  (2013)	   Critically	  ill	  patients	  (phase	  III	  trials)	  N:	  527	  
62	  years	  80	  kg	  65	  %	  	  males	  ALB:	  23.4	  g/L	  	  
Age,	  WGT,	  creatinine	  clearance,	  bilirubin,	  AST,	  ALB	  






al.	  (2015)	   Obese	  and	  non-­‐obese	  laparoscopic	  surgery	  patients	  N:	  20	  obese/	  20	  non-­‐obese	  
34/40	  years	  115/75	  kg	  165/166	  cm	  
Age,	  WGT,	  FFM,	  normal	  fat	  mass,	  intra-­‐operative	  
2-­‐compartment	  model	  with	  FFM	  as	  a	  covariate	  on	  CL,	  CL2,	  V1	  and	  V2.	  With	  FAT	  as	  a	  covariate	  on	  CL	  and	  intra-­‐operative	  state	  as	  a	  covariate	  on	  V1	  and	  V2	  Hannivoort	  
et	  al.	  (2015)	   HV	  N:	  18	  x	  2	  sessions	  
20-­‐70	  years	  51-­‐110	  kg	  9	  male,	  9	  female	  Age	  stratified	  cohorts	  	  (18-­‐34/35.54/55-­‐72	  years)	  
Age,	  WGT,	  HGT,	  BMI,	  sex	  
3-­‐compartment	  model	  with	  weight	  as	  a	  covariate	  on	  CL,	  CL2,	  V1,	  V2,	  V3	  
Kuang	  et	  al.	  (2016)	   Chinese	  patients	  under	  spinal	  anesthesia	  N:	  19	  young/16	  elderly	  
33	  vs.	  69	  years	  71	  vs.	  54	  kg	  172	  vs.	  158	  cm	  ALT	  49	  vs.	  20	  U/L	  Male:female	  7:12	  vs.	  15:1	  
Age,	  WGT,	  HGT,	  sex,	  BMI,	  AST,	  ALT,	  creatinine	  clearance	  
3-­‐compartment	  model	  with	  ALT	  as	  covariate	  on	  CL,	  age	  on	  V1,	  and	  weight	  on	  V2	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3.	  EXPERIMENTAL	  PART:	  CLINICAL	  RESEARCH	  OF	  DEXMEDETOMIDINE	  ON	  HEALTHY	  VOLUNTEERS	  	  3.1	  Aim	  of	  the	  study	  and	  perspectives	  	  	  The	   aim	   of	   this	   study,	   conducted	   on	   healthy	   volunteers,	   was	   to	   explore	   the	  pharmacokinetics	   of	   subcutaneously	   and	   intravenously	   administered	  dexmedetomidine.	   To	   determine	   the	   pharmacokinetic	   parameters	   after	  subcutaneously	   and	   intravenously	   administered	   dexmedetomidine	   both	  explorative	   and	   non-­‐compartmental	   pharmacokinetic	   analysis	   were	   done	  with	  Excel.	   Additionally,	   population	   modeling,	   using	   the	   nonlinear	   mixed	   effects	  model,	  is	  used	  to	  determine	  the	  pharmacokinetics	  of	  intravenously	  administered	  dexmedetomidine.	  	  The	  pharmacokinetics	  of	  intravenously	  administered	  dexmedetomidine	  has	  been	  determined	   in	   several	   studies	   and	   we	   will,	   therefore,	   be	   able	   to	   compare	   our	  results	   with	   the	   previous	   studies.	   The	   values	   of	   intravenous	   clearance	   and	  elimination	  half-­‐life	  from	  five	  different	  studies	  are	  shown	  in	  Table	  2.	  In	  the	  NCA	  we	   will	   be	   able	   to	   determine	   pharmacokinetic	   parameter	   values	   for	  subcutaneously	   administered,	   but	   won´t	   be	   able	   to	   compare	   them	   to	   other	  studies,	   since	   no	   previous	   study	   has	   been	   conducted	   on	   subcutaneously	  administered	   dexmedetomidine.	   Scheinin	   et	   al.	   (1992),	   Kivistö	   et	   al.	   (1994),	  Anttila	   et	   al.	   (2004),	   Iirola	   et	   al.	   (2011),	   Yoo	   et	   al.	   2015	   have	   all	   conducted	  pharmacokinetic	   studies	   on	   extravascularly	   administered	  dexmedetomidine	  on	  healthy	   subjects.	  Hence,	  we	   can	   compare	   the	   result	  with	   the	   result	   from	   these	  studies	   and	   get	   an	   understanding	   of	   how	   good	   the	   subcutaneous	   route	   is	  compared	  to	  the	  other	  extravascular	  routes.	  	  In	  the	  population	  PK	  modeling	  we	  will	  determine	  population	  pharmacokinetics	  through	  a	  compartment	  model	  using	  the	  nonlinear	  fixed	  effects	  model.	  We	  will,	  additionally,	   characterize	   the	   relationship	   between	   individual	   covariate	   effects	  and	  observed	  drug	  exposure.	  Thereby,	  determination	  of	  the	  covariate,	  weight,	  is	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affecting	  the	  pharmacokinetics	  of	  dexmedetomidine.	  These	  findings	  can	  then	  be	  compared	   to	   previous	   results	   of	   PK	   population	   modeling.	   Previously,	   many	  population	   PK	   studies	   of	   intravenously	   administered	   dexmedetomidine	   have	  been	  conducted	  (Table	  3).	  	  	  It	  is	  important	  to	  take	  physiological	  factors,	  such	  as	  age,	  weight,	  height,	  hepatic-­‐	  and	   kidney	   functions,	   into	   consideration	   when	   administering	   drugs.	   By	   using	  covariate	   models	   we	   might	   find	   associations	   between	   the	   covariates	   and	  pharmacokinetics.	   These	   findings	   might	   in	   the	   future	   lead	   to	   individual	   drug	  dosages	  and,	  thereby,	  achieving	  better	  drug	  effect	  and	  less	  adverse	  effects.	  	  Dexmedetomidine	   registered	   in	   ICU	   for	   sedative	   use	   only	   and	   in	   the	   USA	  additionally	  for	  surgical	  procedures.	  However,	  patients	  in	  their	  final	  stage	  of	  life	  might	  need	  medication	  to	  ease	  pain	  and	  anxiety,	  hence,	  the	  anxiolytic,	  sedative,	  and	  analgesic	  effect	  of	  dexmedetomide	  could	  be	  used.	  The	  products,	  Precedex®	  and	  Dexdor®,	   are	   registered	   for	   intravenous	  administration	  only.	  Even	   though	  plenty	   of	   pharmacokinetic	   studies	   have	   been	   conducted	   on	   intravenously	  administered	  dexmedetomidine,	  it	  is	  not	  the	  most	  suitable	  administration	  route	  in	  many	   cases.	   Therefore,	   there	   is	   a	   need	   for	   additional	   administration	   routes.	  Orally	  administrated	  dexmedetomidine	  did	  not	  achieve	  sufficient	  bioavailability	  and,	   hence,	   the	   investigation	   of	   other	   administration	   routes	   is	   important.	   If	  subcutaneously	  administered	  dexmedetomidine	  shows	  good	  pharmacokinetics	  it	  could,	  for	  example,	  be	  used	  in	  drug	  pumps	  for	  cancer	  patients	  in	  their	  final	  stage	  of	  life.	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3.2	  Materials	  and	  Methods	  	  3.2.1	  Volunteer	  study	  	  	  The	   clinical	   phase	   of	   the	   study	   was	   conducted	   in	   ten	   voluntary	   subjects	  compatible	  with	  the	  inclusion	  and	  exclusion	  criteria.	  The	  inclusion	  criteria	  of	  the	  study	   were:	   fluent	   skills	   in	   the	   Finnish	   language	   in	   order	   to	   be	   able	   to	   give	  informed	  consent	  and	  communicate	  with	  the	  study	  personnel,	  age	  of	  18	  years	  or	  older,	  male	  gender,	  a	  weight	  of	  60	  kg	  or	  more,	  and	  a	  written	   informed	  consent	  from	   the	   subject.	   The	   exclusion	   criteria	   included	   everything	   from	   donation	   of	  blood	   and	   participation	   in	   any	   other	   clinical	   study	   to	   existing	   or	   recent	  significant	  disease.	  	  The	   trial	   design	   was	   an	   open,	   two	   period,	   cross-­‐over	   design	   with	   balanced	  randomization,	  with	   a	  wash-­‐out	   period	   of	   at	   least	   7	   days	   between	   consecutive	  administrations.	   The	   study	  was	   conducted	  with	   two	   study	   sessions	  where	   the	  subjects	  received	  dexmedetomidine	  either	  IV	  or	  SC	  at	  the	  first	  session	  and	  vice	  versa	   in	   the	   second	   study	   session.	   However,	   two	   subjects	   out	   of	   ten	   did	   only	  receive	  the	  SC	  administered	  dose.	  	  Prior	  to	  the	  first	  study	  session,	  a	  screening	  of	  the	   participating	   subjects	   was	   conducted.	   The	   screening	   consisted	   of	   both	   a	  review	   of	  medical	   history	   and	   a	   physical	   examination.	   	   Also	   a	   7-­‐day	   follow-­‐up	  after	  both	  study	  sessions	  by	  telephone	  contact	  or	  visit	  was	  conducted.	  	  The	  preparation	   for	   the	  study	  session	  was	   to	  confirm	  whether	   the	   ten	  subjects	  were	   healthy	   and	   still	   fulfilled	   the	   inclusion	   and	   exclusion	   criteria.	   This	   was	  conducted	  by	  contacting	  the	  subjects	  by	  telephone	  in	  the	  evening	  preceding	  the	  first	  study	  session.	  The	  subjects	  were	  informed	  to	  fast	  from	  midnight	  before	  both	  study	  sessions	  and	  only	  water	  intake	  was	  allowed	  during	  this	  period.	  	  The	   general	   study	   outline	   was	   as	   follows:	   In	   the	   morning	   of	   the	   first	   study	  session,	   a	   venous	   catheter	   was	   inserted	   into	   a	   large	   forearm	   vein	   for	   safety	  reasons	   and	   an	   arterial	   catheter	   was	   inserted	   into	   the	   radial	   artery	   for	   blood	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sampling	   and	   blood	   pressure	   monitoring.	   Additionally,	   ECG,	   invasive	   blood	  pressure	  and	  SpO2	  were	  continuously	  monitored.	  	  The	  subjects	  were	  given	  a	  single	  1	  μg/kg	  dose	  of	  dexmedetomidine	  either	  IV	  or	  SC.	   The	   administered	   dexmedetomidine	   (dexmedetomidine	   hydrochloride	   100	  μg	   /ml)	   was	   the	   product	   Dexdor®	   developed	   by	   Orion.	   The	   SC	   dose	   was	  administered	  undiluted	  and	  the	  IV	  dose	  administered	  diluted	  in	  10	  ml	  of	  sodium	  chloride	  solution	  at	  a	  constant	  rate	  during	  10	  min	  using	  an	  infusion	  pump.	  	  The	  subjects	  remained	  in	  a	  semi-­‐recumbent	  position	  after	  cannulation	  until	  the	  end	  of	  the	  study,	  excluding	  time	  for	  bio-­‐breaks	  (rest-­‐room	  visiting	  and	  meals).	  At	  4	   and	   8	   hours	   after	   dexmedetomidine	   administration,	   standard	   meals	   were	  served	  to	  the	  subjects.	  	  At	  10	  hours	  after	  administration,	  a	  follow	  up	  was	  initiated	  if	  the	  subjects	  fulfilled	  the	   surgical	   outpatient	   discharged	   criteria	   used	   at	   Turku	   University	   Hospital	  they	  were	  allowed	  to	  leave	  the	  study	  facility.	  	  This	  general	  study	  outline	  was	  repeated	  at	  the	  second	  study	  session,	  where	  the	  subjects	  received	  the	  other	  dose	  of	  dexmedetomidine,	  either	  IV	  or	  SC	  depending	  on	  the	  first	  study	  session.	  	  	  3.2.2	  Blood	  samples	  and	  their	  handling	  	  Arterial	  blood	  samples,	  with	  a	  volume	  of	  5	  ml,	  were	  collected	  from	  the	  subjects	  immediately	   prior	   to	   administration	   of	   dexmedetomidine	   and,	   thereafter,	   at	   5,	  10,	   15,	   20,	   30,	   45,	   60,	   90,	   120,	   180,	   240,	   300,	   360,	   480	   and	   600	   min	   after	  administration	   to	   determine	   plasma	   concentrations	   of	   dexmedetomidine.	   The	  same	   procedure	  was	   repeated	   at	   the	   second	   treatment	   session	   adding	   up	   to	   a	  total	  of	  160	  ml	  blood	  per	  subject.	  	  The	  collected	  blood	  samples	  were	   immediately	  placed	   in	   ice	   to	  be	  kept	  cooled.	  Subsequently	  a	  refrigerated	  centrifugation	  was	  used	  to	  separate	  the	  plasma	  from	  
42	  	  
	  
the	  collected	  blood	  samples.	  The	  separated	  plasma	  from	  each	  5	  ml	  of	  blood	  was	  stored	  in	  two	  aliquots	  and	  stored	  at	  a	  temperature	  -­‐70	  C.	  	  3.2.3	  Analysis	  of	  dexmedetomidine	  concentrations	  	  To	  measure	  the	  concentration	  of	  dexmedetomidine	  in	  plasma	  a	  validated	  liquid	  chromatographic/mass	   spectrometric	   method	   was	   used.	   These	   measurements	  were	   conducted	   at	   the	   Department	   of	   Pharmacology,	   Drug	   Development	   and	  Therapeutics	  at	  University	  of	  Turku.	  	  The	   measurement	   method	   of	   dexmedetomidine	   is	   based	   on	   a	   previously	  published	  method	   by	   Ji	   et	  al.	   (2004),	   namely;	   reverse-­‐phase	   high-­‐performance	  liquid	   chromatography	   with	   tandem	   mass	   spectrometric	   detection	   (HPLC-­‐MS/MS)	   (Shimadzu	  Prominence	  HPLC	  connected	   to	  an	  AB	  Sciex	  API4000	  mass	  spectrometer).	   The	  mobile	   phase	   in	   liquid	   chromatography	   consisted	   of	   0,1	  %	  formic	   acid	   in	   a	   mixture	   of	   1:1:1	   (v/v/v)	   methanol/acetonitrile/water.	   HPLC-­‐MS/MS	  is	  a	  sensitive	  method,	  and	  a	   lower	  quantitation	   limit	  of	  0.02	  ng/ml	  was	  obtained.	  	  	  3.2.4	  Explorative	  and	  non-­‐compartment	  data	  analysis	  	  The	   explorative	   data	   analysis	  was	   conducted	   on	  Excel,	  where	   all	   data	   for	   each	  subject	   were	   tabled	   and	   plotted.	   Pharmacokinetic	   parameter	   values	   were	  obtained	  through	  NCA	  in	  Excel.	  Additionally,	  the	  compartment	  models	  for	  IV	  and	  SC	  administered	  dexmedetomidine	  were	  determined.	  	  In	  the	  NCA	  the	  AUC0-­‐10	  (from	  zero	  to	  10	  hours)	  and	  AUC0-­‐∞	  (zero	  to	  infinity)	  were	  calculated	   by	   using	   the	   trapezoidal	   rule	   (Equation	   1).	   The	   AUC0-­‐∞	   takes	   the	  concentration	   from	   10	   hours	   onward	   in	   consideration,	   whereas	   AUC0-­‐10	   only	  calculates	  the	  total	  drug	  exposure	  to	  time-­‐point	  10	  hours.	  The	  last	  segment	  was	  calculated	   by	   dividing	   the	   concentration	   at	   time-­‐point	   10	   hours	   with	   the	  elimination	  rate	  constant,	  ke,	  which	  was	  obtained	  by	  using	  regression	  analysis	  on	  the	  three	  last	  points.	  The	  both	  AUCs	  were	  calculated	  for	  all	  subjects	  after	  both	  IV	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Figure 9.  Plots of plasma concentration versus time for drug showing a one-
compartment model. a) The plasma concentration versus time showing an exponential 
curve, whereas b) is the plasma concentration in semilogarithmic scale versus time 
showing a linear curve. (Dhillon and Gill 2006) 	  	  To	  determine	  if	  it	  is	  a	  two-­‐compartment	  model,	  the	  plasma	  concentration	  versus	  time	   is	   plotted	   in	   the	   same	   manner	   as	   previously	   mentioned,	   however,	   a	  different	   plot	   is	   obtained	   if	   it	   is	   a	   two-­‐compartment	  model.	   As	   can	   be	   seen	   in	  Figure	  10,	  a	  biexponential	  curve	  is	  obtained	  in	  plot	  (a),	  resembling	  the	  curve	  (a)	  in	   Figure	   9.	   However,	   when	   plotting	   in	   a	   semilogarithmic	   scale	   a	   two-­‐phased	  linear	   curve	   is	   obtained,	   which	   indicates	   that	   it	   is	   a	   two-­‐compartment	  model.	  Every	  obtained	  phase	  indicates	  the	  amount	  of	  compartments.	  Therefore,	  a	  three-­‐phased	  linear	  curve	  indicates	  that	  the	  drug	  exhibits	  a	  three-­‐compartment	  model.	  	  	  
Figure 10. Plots of concentration versus time for a drug showing a two-compartment 
model. a) The plasma concentration versus time showing an exponential curve, 
whereas b) is the plasma concentration in semilogarithmic scale versus time, showing 
a two-phased linear curve. (Dhillon and Gill 2006) 	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3.2.5	  Pharmacometric	  analysis	  	  	  In	   the	   pharmacometric	   analysis	   the	   time	   course	   of	   the	   dexemedetomidine	  concentrations	   after	   IV	   administration	   were	   analyzed	   through	   a	   two-­‐	  compartment	   linear	   model,	   using	   nonlinear	   mixed	   effect	   modeling	   (NONMEM	  7.1.3,	  ICON	  Development	  Solutions,	  Ellicott	  City,	  MD,	  USA).	  	  Additionally,	  a	  three-­‐compartment	   linear	  model	  was	   tested	   to	  determine	   if	   three-­‐compartment	  data	  describes	  the	  data	  better.	  	  To	  be	  able	  to	  analyze	  the	  original	  IV	  concentration	  data	  with	  NONMEM	  an	  input	  data	  file,	  where	  the	  data	  were	  set	  in	  a	  certain	  way,	  had	  to	  be	  constructed.	  In	  the	  input	  data	  file	  the	  columns	  were	  built	  up	  with	  different	  data	  items	  and	  the	  rows	  had	  the	  recorded	  values.	  The	  following	  columns	  were	  used	  in	  our	  input	  data	  file;	  identification	  (ID),	  where	  we	  numbered	  the	  subjects	  from	  one	  to	  ten;	  dependent	  value	   (DV),	   which	   equals	   concentration;	   time	   (TIME);	   amount	   given	   (AMT),	  which	  ought	  to	  be	  set	  in	  mass	  units;	  missing	  dependent	  value	  (MDV),	  which	  gets	  a	  value	  of	  1	  whenever	  a	  drug	  dose	  is	  given;	  the	  rate	  of	  the	  infusion	  (RATE);	  and	  the	  covariate’s	  weight	  (WT).	  	  	  After	  the	  data	  file	  was	  set	  correctly,	  the	  following	  step	  was	  to	  build	  up	  a	  record,	  which	  can	  be	  translated	  with	  the	  NONMEM	  translator	  (NM-­‐TRAN).	  This	  record	  is	  called	  control	   file	  and	  was	  built	  up	  with	  blocks,	  which	  by	  codes	  describe	  given	  things.	  Every	  separate	  block	  was	  marked	  with	  a	  dollar	  sign,	  for	  example;	  $PROB,	  which	  stated	  the	  problem	  we	  were	  going	  to	  solve;	  $INPUT,	  which	  is	  the	  names	  of	  the	  data	  records	  in	  the	  input	  data	  file;	  and	  block	  $DATA,	  which	  is	  the	  name	  of	  the	  input	  data	  file	  developed	  earlier.	  With	  NONMEM	  one	  can	  use	  pre-­‐written	  models	  from	  the	  flexible	  library	  to	  solve	  pharmacokinetic	  problems.	  This	  library	  is	  called	  Predictions	   for	   population	   pharmacokinetics	   (PREDPP),	   which	   consists	   of	  several	   models	   named	   ADVAN	   subroutines	   (ADVAN1-­‐12).	   Furthermore,	   each	  ADVAN	  can	  have	  a	  specified	  TRAN	  subroutine,	  which	  determines	  the	  parameters	  that	  ought	  to	  be	  defined	  in	  the	  $PK	  block.	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After	  the	  data	  file	  was	  set	  correctly,	  a	  NONMEM	  control-­‐file	  guiding	  the	  modeling	  was	  built	  up.	  The	  data	  was	  modeled	  with	  the	  pre-­‐defined	  model	  ADVAN3,	  which	  is	  a	  two-­‐compartment	  linear	  model,	  without	  oral	  absorption.	  The	  TRANS4	  model	  was	  used,	  to	  transform	  the	  rate	  constants	  to	  the	  pharmacokinetic	  parameters	  CL,	  V1,	  Q,	  and	  V2.	  V1	   is	   the	  volume	  of	  distribution	   in	   the	  central	   compartment,	  V2	  the	   volume	   of	   distribution	   in	   the	   second	   compartment,	   Q	   the	   inter-­‐compartmental	  CL	  between	  compartment	  one	  and	   two,	   and	  CL	   the	  elimination	  clearance.	  The	  population	  parameter	  values	  (THETAS)	  for	  CL,	  V1,	  Q,	  and	  V2	  were	  all	   determined	   through	   the	   analysis.	   In	   the	   pharmacokinetic	   model	   the	  population	   parameter	   values	  were	   scaled	  with	   covariate	   body	  weight	   (WT)	   as	  follows;	   TVCL=THETA(1)*(WT/78)**0.75,	   for	   CL;	   TVV=THETA(2)*(WT/78)**1	  for	  CL;	  Q=THETA(3)*(WT/78)**0.75,	  Q;	  and	  V2=THETA(4)*(WT/78)**1,	  for	  V2.	  The	   inter-­‐individual	   variabilities	   (ETA1	   and	   ETA	   2)	   for	   the	   pharmacokinetic	  parameters	   CL	   and	   V1	   were	   modeled	   by	   exponential	   random	   effects:	   CL=	  TVCL*EXP(ETA(1))	  and	  V1=TVV*EXP(ETA(2)),	   respectively.	  The	   residual	   intra-­‐	  individual	   variance	   (THETA(5))	   was	   modeled	   in	   the	   $ERROR	   block	   using	   a	  combined	  additive	  and	  proportional	  error	  model.	  	  The	  same	  was	  conducted	  for	  the	  three-­‐compartment	  model.	  However,	  in	  this	  we	  used	  the	  PREDPP	  ADVAN11,	  which	  is	  a	  three-­‐compartment	  linear	  model	  without	  an	   absorption	   phase,	   and	   additional	   PK	   parameters	   (Q3	   and	   V3)	   had	   to	   be	  determined	  in	  this	  PREDPP	  model.	  Q3	  is	  the	  inter-­‐compartmental	  clearance	  from	  the	   third	   compartment	   to	   the	   first	   compartment,	   and	   V3	   the	   volume	   of	  distribution	  in	  the	  third	  compartment.	  	  	  After	  the	  control	  files	  were	  properly	  built	  up	  with	  all	  necessary	  blocks,	  the	  NM-­‐TRAN	  was	  used.	  The	  NM-­‐TRAN	  reads	  and	  translates	  the	  input,	  the	  data	  file	  and	  the	   built	   record,	   together	  with	   a	   fortran	   compiler	   to	   a	   format	   compatible	  with	  NONMEM	  to	  do	  the	  modeling.	  During	  the	  translation	  the	  NM-­‐TRAN	  translates	  the	  records	  into	  several	  NONMEM	  input	  files.	  Subsequently	  the	  NONMEM	  step	  itself	  was	  run.	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3.3	  Results	  	  	  3.3.1	  Pharmacokinetics	  of	  dexmedetomidine	  from	  NCA	  	  In	  the	  explorative	  data	  analysis	  both	  plasma	  concentrations	  (ng/mL)	   for	   the	  IV	  administrated	  dose	  and	  the	  SC	  administered	  dose	  were	  plotted	  against	  time	  (h)	  to	  obtain	  graphs.	  For	  each	  subject	  the	  plasma	  concentration,	  after	  both	  IV	  and	  SC	  administered	   dexmedetomidine,	   are	   plotted	   against	   time	   and	   shown	   in	   Figure	  11.	  For	  subject	  9	  and	  10	  only	  the	  SC	  dose	  was	  administered.	  As	  can	  be	  seen,	  IV	  dose	  achieved	  much	  higher	  concentrations	   than	   the	  SC	  administered	  dose.	  The	  highest	  plasma	  concentration	  (Cmax)	  after	  the	  IV	  dose	  was	  achieved	  in	  subject	  2	  with	   a	   value	   of	   2.82	   ng/mL,	   whereas	   the	   lowest	   plasma	   concentration	   was	  achieved	   in	   subject	   5	   with	   a	   value	   of	   1.72	   ng/mL.	   	   The	   highest	   plasma	  concentration	  after	  the	  SC	  dose	  was	  achieved	  in	  subject	  10	  with	  a	  value	  of	  0.485	  ng/mL,	  whereas	  the	  lowest	  value	  was	  seen	  in	  subject	  4,	  0.112	  ng/mL.	  	  	  After	   the	   SC	   dose	   the	   highest	   plasma	   concentration	   is	   for	   the	   majority	   of	   the	  subjects	  achieved	  at	  15	  minutes	  (0.25	  hours),	  however,	  for	  subject	  3	  and	  9	  at	  30	  minutes	  (0.5	  hours).	  For	  the	  majority	  of	  the	  subjects	  the	  Tmax	  were	  achieved	  10	  minutes	  (0.1667	  hours)	  after	  the	  IV	  administration	  rather	  than	  at	  the	  first	  time-­‐point	  (0.083	  hours/	  5	  minutes).	  This	  is	  because	  the	  dose	  was	  given	  as	  a	  10	  min	  infusion,	  not	  as	  a	  bolus	  injection.	  	  
	  	  	  	  
48	  	  
	  
Figure 11. The plasma concentration of IV and SC administered dexmedetomidine 
versus time for all subjects. In subject 9 and 10 only the SC plasma concentration was 
obtained. On the y-axis is the concentration in mcg/L and on the x-axis the time in 
hours. 	  	  
49	  	  
	  
Additionally,	   all	   the	   subjects’	   concentration-­‐time	   curves	   were	   combined	   to	   a	  unified	  graph,	  to	  easily	  clarify	  the	  difference	  among	  the	  subjects	  (Figure12).	  	  a)	  
b)	  
Figure 12. The combined plasma concentration-time for all subjects after both IV and 
SC administered dexmedetomidine. On the y-axis is the concentration in mcg/L and 
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Through	  NCA	  the	  AUC0-­‐∞	  and	  AUC010	  were	  calculated	   for	  all	  subjects	  both	  after	  the	   IV	  and	  the	  SC	  dose,	  and	  are	  shown	   in	  Table	  4.	   	  Additional	  pharmacokinetic	  parameters	  can	  be	  seen	  in	  Table	  4.	  	  
Table 4. The calculated PK parameter values through NCA. a) The calculated values 
for AUC0-∞, AUC0-10, CL, and t1/2 for all eight subjects after the IV dose. b) The 
calculated values for AUC0-∞, AUC0-10, CL/F, terminal half-life, F, F% for all ten 
subjects after the SC dose. F, F%, and CL were not able to calculate for subject 9 and 
10. 
a) 
Subject	   1	   2	   3	   4	   5	   6	   7	   8	  AUC0-­‐∞	  (ng*min/mL)	   0.031	   0.040	   0.024	   0.032	   0.043	   0.031	   0.036	   0.034	  AUC0-­‐10	  	  (ng*min/mL)	   0.031	   0.039	   0.0240	   0.031	   0.042	   0.030	   0.035	   0.033	  CL	  (L/h)	   38	   35	   51.8	   45	   35	   43	   33	   39	  t	  1/2	  (h)	   1.40	   2.2	   2.0	   2.2	   1.9	   2.3	   2.3	   2.3	  	  
b) 
	  
Subject	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	  AUC0-­‐∞	  (ng*min/ml)	   0.022	   0.023	   0.026	   0.014	   0.039	   0.032	   0.028	   0.13	   0.031	   0.044	  AUC0-­‐10	  (ng*min/ml)	   0.018	   0.017	   0.019	   0.0086	   0.026	   0.024	   0.022	   0.020	   0.022	   0.031	  F	   0.72	   0.65	   1.1	   0.58	   0.91	   1.0	   0.78	   3.8	   -­‐	   -­‐	  F%	   72	   65	   108	   58	   91	   104	   78	   376	   -­‐	   -­‐	  CL/F	  (L/h)	   53	   54	   48	   78	   38	   42	   42	   10	   44	   30	  Terminal	  half-­‐life	  (h)	   3.8	   5.8	   5.5	   8.8	   6.2	   5.2	   4.0	   40	   6.1	   5.7	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Finally,	   the	   population	   mean	   parameter	   values	   and	   standard	   deviations	   (SD)	  were	   calculated	   for	   all	   PK	   parameters	   after	   the	   IV	   and	   the	   SC	   dose,	   and	   are	  shown	  in	  Table	  5.	  	  
 
Table 5. Mean PK parameter values and standard deviations (SD) for a) IV and b) SC 
administered dexmedetomidine.  a)	  	  	  	  	  b)	  	  	  	  	  	  	  	  The	   average	   AUC0-­‐∞	   value	   for	   IV	   and	   SC	   showed	   similarities,	   indicating	   same	  total	  drug	  exposure.	  However,	  the	  AUC0-­‐∞	  values	  for	  the	  SC	  dose	  have	  high	  SDs,	  and	  as	  can	  be	  seen	  in	  Table	  4	  the	  values	  range	  from	  0.0143	  to	  0.129	  ng*min/ml.	  The	  value	  of	  apparent	  clearance	  was	  higher	  after	  the	  SC	  dose,	  and	  also	  a	  higher	  SD	  was	  obtained,	   indicating	   significant	   variability	   (Table	  5).	   The	   terminal	   half-­‐life	   is	   much	   longer	   after	   the	   SC	   administration,	   9	   hours	   versus	   2	   hours.	  Additionally,	   the	   SD	   for	   the	   elimination	   half-­‐life	   after	   the	   SC	   dose	   is	   10	   hours,	  whereas	  it	  is	  only	  0.3	  hours	  for	  the	  IV	  dose.	  	  The	  calculated	  average	  F	  %	  shows	  a	  high	  bioavailability,	  however,	  the	  standard	  deviation	  is	  very	  high.	  
Pharmacokinetic	  
parameters	  
Mean	   SD	  




F	   1.2	   1.2	  
F%	   119	   99	  




T	  1/2	  (h)	   9.1	   10	  




Cmax	  (ng/mL)	   0.29	   0.096	  
Pharmacokinetic	  
parameters	  
Mean	   SD	  
AUC	  0-­‐∞	  (ng*min/ml)	   0.034	   0.0055	  
	  
CL	  (L/h)	   40	   5.9	  
T	  1/2	  (h)	   2.1	   0.30	  
Tmax	  (h)	   0.15	   0.036	  
Cmax	  (ng/mL)	   2.4	   0.34	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3.3.2	  Population	  pharmacokinetics	  of	  dexmedetomidine	  	  In	  the	  population	  modeling,	  data	  from	  eight	  healthy	  volunteers	  were	  used.	  They	  were	  all	  males,	  with	  ages	  ranging	  from	  19	  to	  22,	  weight	  ranging	  from	  71	  to	  91	  kg.	  Only	  the	  covariate,	  weight,	  was	  taken	   into	  account	   in	  the	   final	  covariate	  model.	  The	  effect	  of	  the	  covariate	  was	  modeled	  by	  allometrically	  scaling	  the	  parameters.	  	  The	   original	   data	   of	   IV	   administered	   dexmedetomidine	   exhibited	   at	   least	   two	  linear	   phases	   when	   plotted	   as	   log	   concentration	   versus	   times	   (Figure	   13).	  Because	  we	  were	  not	  sure	  of	  the	  third	  linear	  phase	  in	  the	  middle	  we	  decided	  to	  test	   both	   a	   two-­‐compartment	   and	   a	   three-­‐compartment	  model	   in	   our	   analysis.	  However	   the	   three-­‐compartment	   model	   did	   not	   fit	   properly.	   Thereby,	   a	   two-­‐compartment	   PK	   model,	   with	   allometrically	   scaled	   parameters,	   on	   a	   log-­‐scale	  was	  used	  to	  describe	  our	  data.	  
	  
Figure 13. Log plasma concentration plotted against time to determine the amount of 
compartments we should use in the IV population model. *= the possible third phase. 
The concentrations are the mean plasma concentrations for all 8 subjects at given time 

















Phase	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seen	   in	   Table	   6.	   As	   can	   be	   seen	   from	   the	   standard	   of	   error	   (SE)	   values,	   the	  pharmacokinetic	   parameters	   and	   inter-­‐individual	   variabilities	   were	   estimated	  with	   good	   precision.	   Additionally,	   from	   the	   inter-­‐individual	   variability	   values,	  one	  can	  determine	  that	  BSV	  is	  low.	  	  
Table 6. Population pharmacokinetic parameters for the IV model of 
dexmedetomidine. SE, standard error of estimates; CI, confidence interval; DV, 
dependent value; IPRED, individual prediction; PRED, population prediction. 
	  A	   bootstrap	   analysis	   with	   1000	   replications	   was	   conducted	   to	   evaluate	  parameter	  ambivalence.	  The	  median	  and	  95	  %	  confidence	  intervals	  (CI)	  from	  the	  bootstrap	   analysis	   can	   be	   seen	   in	   Table	   6.	   Since	   the	   bootstrap	   analysis	   gave	  parameter	  values	  in	  line	  with	  the	  obtained	  values,	  we	  can	  assume	  that	  the	  model	  is	  robust	  and	  the	  parameter	  values	  are	  good	  estimates	  for	  the	  population.	  	  To	   evaluate	   the	   final	   population	  model	   several	   diagnostic	   plots,	   were	   plotted:	  observations	   vs.	   prediction,	   individual	   weighted	   residual	   (IWRES),	   conditional	  
Parameter	   Covariate	  model	   Population	  
estimates	  
Bootstrap	  results	  
	   	   Mean	   SE	   Median	   95	  %	  CI	  
θ1	  =	  THETA1	  (L/h)	   CL1=	  THETA	  
(1)*(WT/78)**0.75	  
39,6	   2,02	   38,8	   34.7,	  42.3	  
θ2	  	  =	  THETA2	  (L)	   V1=	  THETA	  (2)*	  
(WT/78)**1	  
13,7	   0,987	   14,1	   12.8,	  16.5	  
θ3	  	  =	  THETA3	  (L/h)	   CL2=	  THETA	  
(3)*(WT/78)**0.75	  
116	   6,77	   116,2	   103.1,	  129.1	  
θ4	  	  =	  THETA4	  (L)	   V2=THETA	  (4)*	  
(WT/78)**1	  
77	   3,14	   76,2	   69.5,	  81.1	  
θ5	  =THETA5	  (ng/ml)	   	   0,0155	   0,0179	   0,1595	   0.131,	  0,185	  
Interindividual	  
variability	  
	   	   	   	   	  
ω21 	   	   0,0154	   0,00699	   0,01299	   0.00334,	  0.02736	  
ω22	   	   0,0163	   0,00203	   0,02184	   0.00715,	  0.05343	  
Median	  prediction	  
erros	  
	   	   	   	   	  
DV	  vs	  PRED	  (%)	   -­‐0,29	   	   	   	   	  
DV	  vs	  IPRED	  (%)	   1,65	   	   	   	   	  
Median	  absolute	  
prediction	  errors	  
	   	   	   	   	  
DV	  vs	  PRED	  (%)	   13,12	   	   	   	   	  
DV	  vs	  IPRED	  (%)	   8,26	   	   	   	   	  
54	  	  
	  
weighted	  residuals	  (CWRES),	  observed/predicted	  versus	  time	  graphs	  and	  visual	  predicted	  check.	  	  In	  Figure	  14,	  it	  can	  be	  seen	  that	  the	  observed	  plasma	  concentrations	  are	  in	  line	  with	   the	   predicted	   individual	   and	   population	   plasma	   concentrations,	   thereby,	  showing	  that	  the	  structural	  model	  fits	  the	  data.	  The	  values	  for	  median	  prediction	  error	   (MDPE)	   describing	   the	   bias	   and	   median	   absolute	   prediction	   error	  (MDAPE)	  describing	   the	  amount	  of	  variance,	  are	  small	   for	  both	  population	  and	  individual	  predictions,	  also	  indicating	  a	  good	  quality	  of	  fit	  for	  the	  model.	  	  a)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  b)	  
	  
Figure 14. Observed dexmedetomdine concentrations versus a) indvidual and b) 
population predictions. Median predicted errors (MDPE) and median absolute 
predicted errors (MDAPE) are stated in both graphs. 
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a)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
b)	  
Figure 15. a) Individual weighted residuals (IWRES), where the residuals are 
obtained from the individual model. The IWRES is both plotted against the 
independent value, time, (left), and the dependent value, concentration (right). b) 
Conditional weighted residuals (CWRES), plotted against the independent value, 
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a)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  b)	  	  	  	  	  	  	  
Figure 16. Observed/predicted versus time for a) individual and b) population data.  	  In	  Figure	  17,	  the	  results	  of	  a	  visual	  predictive	  check	  (VPC)	  are	  shown.	  VPC	  was	  performed	   to	   evaluate	   the	   predictability	   of	   the	  model.	   This	  was	   performed	   by	  simulating	  1000	  data	  sets.	  For	  the	  model	  to	  be	  good	  all	  observed	  data	  should	  lie	  inside	   the	   95%	   confidence	   interval	   of	   the	   simulated	  data.	   As	   Figure	   17	   shows,	  this	  was	  the	  case	  with	  the	  model	  presented	  here.	  	  	  
	  
Figure 17. Graph plotting the results of visual predictive check (VPC). Observed 
concentrations are shown with gray dots together with median (black line) and 95% 
confidence interval (dotted line) of the observed data. The blue areas describe the 
95% confidence interval of the median and 95% confidence interval bounds of 1000 



















































































































































































































































3.4	  Discussion	  	  In	   the	   study	   we	   investigated	   the	   pharmacokinetics	   of	   dexmedetomidine	   after	  both	   IV	   and	   SC	   doses	   in	   healthy	   volunteers.	   In	   the	   NCA	   both	   IV	   and	   SC	  pharmacokinetic	  parameters	  were	  calculated.	  From	  the	  individual	  data	  one	  can	  clearly	   see	   that	   there	   are	   variations	   in	   drug	   exposure	   between	   subjects.	   To	  clarify	   the	   variability	   in	   plasma	   concentrations,	   the	   plasma	   concentration-­‐time	  graphs	  of	  all	  subjects	  were	  combined	  (Figure	  12).	  	  These	  variabilities	  may	  be	  due	  to	  different	  factors,	  for	  example,	  physiological	  factors	  such	  as	  weight	  and	  hepatic	  function	  (Mould	  and	  Upton	  2012).	  However,	  it	  was	  not	  possible	  to	  determine	  the	  factors	  affecting	  the	  variability	  in	  NCA.	  	  	  The	   average	   pharmacokinetic	   values	   after	   IV	   dexmedetomidine	   showed	  much	  smaller	   SD	   values	   than	   after	   the	   SC	   dose,	   and	   as	   can	   be	   seen	   in	   Figure	   12	   the	  plasma	  concentration	  curves	  for	  the	  IV	  doses	  resembled	  each	  other	  much	  more	  than	   the	  SC	  plasma	  concentrations.	   Since	   the	  drug	   is	   injected	   IV	  no	  absorption	  phase	  is	  seen	  and,	  therefore,	  every	  subject	  was	  administered	  the	  same	  amount	  of	  drug	   per	   kg	   into	   the	   blood.	   This	  might	   be	   one	   factor	  why	   the	   inter-­‐individual	  variation	   is	   less	   than	  after	   the	  SC	  dose.	  The	  parameter	  values	   from	  the	   IV	  dose	  are	   in	   line	   with	   the	   previous	   studies,	   which	   were	   both	   conducted	   on	   healthy	  subjects.	  For	  example,	  the	  elimination	  half-­‐life	  varied	  from	  2.0	  to	  3.1	  hours	  and	  clearance	  from	  39	  to	  49.2	  L/h	  (Table	  1).	  	  The	   pharmacokinetic	   parameter	   values	   obtained	   for	   the	   SC	   administered	   dose	  showed	  apparent	  inter-­‐individual	  variation.	  This	  can	  be	  assumed	  from	  the	  high	  SD	  values	  in	  Table	  5	  and	  also	  seen	  in	  Figure	  12.	  Since	  the	  drug	  is	  administered	  SC	  it	  ought	  to	  be	  absorbed	  into	  the	  blood.	  The	  absorption	  phase	  can,	  additionally,	  to	  other	   factors,	  differ	   from	  subject	   to	  subject,	   therefore,	  giving	  a	  higher	  variation	  than	   after	   the	   IV	   dose.	   However,	   in	   this	   case	   the	   main	   reason	   for	   the	   high	  variation	  is	  not	  due	  to	  inter-­‐individual	  variability	  between	  all	  subjects.	  Instead	  it	  is	  the	  data	  from	  subject	  8	  that	  makes	  these	  high	  SD	  values.	  As	  can	  be	  seen	  from	  Figure	  12	  the	  plasma	  concentration	  curve	  differ	  greatly	  from	  the	  others	  curves	  in	  the	   elimination	   phase.	   In	   the	   elimination	   phase	   the	   curve	   starts	   to	   ascend,	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therefore,	   giving	   an	   AUC0-­‐∞	   value	   of	   0.13	   ng*min/mL,	   which	   is	  multiple	   times	  bigger	  than	  the	  others	  AUC0-­‐∞	  values.	  The	  bioavailability	  value	  of	  376	  %	  for	  the	  8th	  subject	  is	  also	  tremendously	  affecting	  the	  bioavailability	  average.	  The	  mean	  pharmacokinetic	  parameter	  values,	  when	  the	  8th	  subject	  is	  removed,	  are	  shown	  in	   Table	   7,	   and	   it	   can	   clearly	   be	   seen	   that	   the	   SD	   are	   lower.	   Additionally,	   the	  bioavailability	   value	   was	   significantly	   lower,	   82	   %	   compared	   to	   119	   %.	   One	  reason	  for	  the	  ascending	  phase	  in	  subject	  8	  could	  be	  that	  an	  amount	  of	  the	  dose	  was	  left	  at	  the	  injection	  site	  and	  later	  absorbed	  to	  the	  blood.	  	  




Average	   SD	  
AUC0-­‐∞	  (ng*min/mL)	   0.029	   0.0085	  
F	   0.82	   0.18	  
F%	   82	   17.9	  
CL/F	  (L/h)	   48	   12	  
T	  1/2	  (h)	   5.7	   1.4	  
Tmax	  (h)	   0.73	   1.2	  
Cmax	  (ng/mL)	   0.30	   0.095	  	  The	  obtained	  mean	  values	  for	  clearance	  and	  elimination	  half-­‐life	  after	  IV	  are	   in	  line	  with	  results	  from	  previous	  studies	  (Kivistö	  et	  al.	  1994:	  Karol	  and	  Maze	  2000:	  Anttila	   et	   al.	   2003:	   Iirola	   et	   al.	   2011,	   Product	  monograph:	   Precedex®	   Hospira	  2016).	  This	  can,	  additionally,	  be	  seen	  when	  comparing	  Table	  2	  and	  Table	  5a.	  The	  obtained	  mean	  pharmacokinetic	  parameter	  values	  after	  SC	  can,	  however,	  cannot	  be	   compared	   to	   other	   studies.	   Clearance	   is	   in	   line	   with	   the	   values	   for	   other	  administration	   routes,	   but	   the	  mean	   elimination	   half-­‐life	   is	   far	   away	   from	   the	  elimination	  half-­‐lives	   of	   other	   administration	   routes.	  When	   the	  8th	   subject	  was	  removed,	  the	  elimination	  half-­‐life	  was	  shortened	  from	  9	  hours	  to	  5.5	  hours.	  	  This	  is	  in	  line	  with	  the	  elimination	  half-­‐life	  of	  transdermal	  administration	  (Kivistö	  et	  
al.	  1994).	  The	  bioavailability	  of	  119	  %,	  indicating	  a	  total	  absorption,	  is	  not	  either	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in	  line	  with	  the	  other	  administration	  routes.	  The	  closest	  is	  the	  IM	  bioavailability	  of	  103.6	  %,	  also	  indicating	  total	  absorption	  (Anttila	  et	  al.	  2003).	  However,	  when	  the	   8th	   subject	  was	   removed	   the	   bioavailability	  was	   lowered	   to	   82	  %,	  more	   in	  line	  with	  the	  other	  administration	  routes	  (Table	  1).	  	  	  Population	  modeling,	  with	  nonlinear	  mixed	  effect	  modeling,	  was	  utilized	  to	  study	  the	   pharmacokinetics	   of	   dexmedetomidine	   after	   IV	   dose.	   The	   aim	   of	   the	   study	  was	  also	  to	  investigate	  the	  pharmacokinetics	  of	  the	  SC	  dose	  through	  population	  modeling,	   however,	   this	  was	   not	   conducted	   due	   to	   lack	   of	   time.	   It	  would	   have	  been	   interesting	   to	   conduct	   population	   modeling	   on	   subcutaneously	  administered	  dexmedetomidine,	  since	  population	  modeling	  has	  never	  been	  done	  on	  SC	  administered	  dexmedetomidine.	  IV	  population	  modeling	  has,	  on	  the	  other	  hand,	  been	  utilized	  before.	  	  Both	   three-­‐compartment	   and	   two-­‐compartment	  models	   were	   constructed,	   but	  the	   two-­‐compartment	   model	   described	   the	   concentration	   of	   dexmedetomdine	  better.	  The	  final	  two-­‐compartment	  population	  model	  showed	  good	  quality	  of	  fit,	  as	  can	  be	  seen	  in	  Figure	  14-­‐17.	  The	  two-­‐compartment	  model	  has	  also	  been	  used	  in	   previous	   studies	   (Table	   3).	   However,	   both	   three-­‐compartment	   models	   and	  one-­‐compartment	  models	  have	  also	  been	  used	  (Table	  3).	  	  	  The	   elimination	   clearance	   value	  was	   almost	   identical	  with	   the	  mean	   clearance	  value	  obtained	   through	  NCA,	  but	  had	   less	  variation	   than	   in	   the	  NCA.	  When	   the	  parameter	   values	   are	   compared	  with	   previous	   PK	  population	   analysis	   one	   can	  see	  that	  our	  values	  are	  similar	  to	  previous	  studies.	  The	  elimination	  clearance	  is	  almost	  identical	  with	  the	  value	  obtained	  in	  the	  study	  conducted	  by	  Välitalo	  et	  al.	  (2013)	   (Table	   8).	   The	   inter-­‐compartmental	   clearance	   that	   we	   obtained	   in	   our	  study	  was	  116	  L/h,	  a	  value,	  which	  in	  previous	  studies	  has	  ranged	  from	  82.2	  L/h	  to	  183	  L/h.	  The	  value	   for	   the	  volume	  of	  distribution	   in	   compartment	  one	   is	   in	  line	  with	  the	  results	  from	  studies	  conducted	  by	  Talke	  et	  al.	  (1997)	  and	  Iirola	  et	  
al.	  (2012),	  whereas	  the	  volume	  of	  distribution	  for	  compartment	  two	  is	  less	  than	  in	  all	  previous	  mentioned	  studies	  (Table	  8).	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All	  of	   these	  studies	  were	  conducted	  on	  patients	   in	   the	   ICU,	  whereas	  ours	  were	  conducted	   on	   healthy	   volunteers.	   The	   physiology	   in	   patients	   and	   healthy	  volunteers	   may	   differ	   because	   differences	   in	   regional	   blood	   flow	   (Venn	   et	   al.	  2002).	  	  
Table 8. Parameter values obtained in population pharmacokinetic studies in patients. 
CL= elimination clearance, CL2= inter-compartmental clearance, V1= central volume 
of distribution, V2= volume of distribution in second compartment. 
	  	  Studies	  have	  also	  been	  done	  on	  healthy	  volunteers	  and	  our	  elimination	  clearance	  parameter	  value	  resembles	  more	  the	  results	  obtained	  in	  these	  studies	  (Table	  9).	  The	   volume	   of	   distribution	   of	   compartment	   one	   is	   almost	   similar	   to	   the	   value	  obtained	  in	  the	  study	  conducted	  by	  Dutta	  and	  colleagues	  (2000).	  Also	  our	  second	  volume	  of	  distribution	  value	  resembles	   the	  result	   in	   this	  study.	  The	  two	  others	  have	  much	   lower	   volume	   of	   distribution	   values	   in	   compartment	   two,	   but	   this	  might	  be	  because	  the	  model	  was	  built	  as	  a	  three-­‐compartment	  model.	  	  	  
Table 9. Parameter values obtained in population pharmacokinetic studies in healthy 
volunteers. CL= elimination clearance, CL2= inter-compartmental clearance, V1= 
central volume of distribution, V2= volume of distribution in second compartment. 	  Parameters	   Dyck	  et	  al.	  (1993b)	   Dutta	  et	  al.	  (2002)	   Hannivoort	   et	   al.	  (2015)	  C1	  (L/h)	   25.1	   33	   41.2	  C2	  (L/h)	   136	   50	   179	  V1	  (L)	   7.99	   13	   1.8	  V2	  (L)	   13.8	   55	   30.3	  	  
Parameters	   Talke	  et	  al.	  	  (1997)	   Venn	  et	  al.	  (2002)	   Iirola	  et	  al.	  (2012)	   Välitalo	  et	  al.	  (2013)	  C1	  (L/h)	   45.1	   49.2	   57.0	   39	  C2	  (L/h)	   82.2	   135	   183	   -­‐	  V1	  (L)	   16.6	   44.1	   12.3	   104	  V2	  (L)	   85.5	   105	   132	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The	   only	   covariate	   taken	   into	   account	   in	   our	   study	  was	   the	   body	  weight.	   The	  effect	  of	  weight	  was	  on	  clearance	  and	  volume	  of	  distribution	  was	  modeled	  using	  allometry.	   From	   the	   result,	   lower	   OFV,	   we	   can	   determine	   that	   the	   covariate,	  weight,	   improved	   the	  model´s	   goodness	   of	   fit.	   Additionally,	   lowering	   the	   inter-­‐individual	  variability,	   as	   can	  be	   seen	   from	   the	   low	  values	   in	  Table	  6.	  However,	  since	   the	   study	  was	   conducted	   on	   young	   and	   healthy	   volunteers	  we	   could	   not	  determine	   any	   other	   covariate	   effects	   on	   pharmacokinetic	   parameters.	   In	   the	  study	   conducted	  by	  Talke	   and	   colleagues	   (1997)	   they	   could	  not	  determine	   the	  effect	  of	  weight	  on	  the	  pharmacokinetic	  parameters.	  However,	   it	  has	   in	  several	  studies	   been	   shown	   that	   weight	   affects	   the	   pharmacokinetic	   parameters.	   For	  example,	  in	  the	  study	  conducted	  by	  Välitalo	  et	  al.	  (2013)	  on	  critically	  ill	  patients	  it	  was	  shown	  that	  weight	  affected	  clearance	  and	  central	  volume	  of	  distribution,	  and	   in	   the	   study	   conducted	   by	  Hannivoort	   et	  al.	   (2015)	   on	   healthy	   volunteers	  was	   it	   also	   shown	   that	   weight	   had	   an	   influence	   on	   the	   pharmacokinetic	  parameters	  CL,	  CL2,	  V1,	  and	  V2.	  	  	  	  3.5	  Conclusion	  	  The	  obtained	  pharmacokinetic	  parameters	  from	  NCA	  for	  IV	  were	  in	  line	  with	  the	  results	   from	  previous	   studies.	   For	   the	   SC	  dose	   the	  pharmacokinetic	   parameter	  values	   had	   high	   SD	   indicating	   high	   inter-­‐individual	   variations.	   However,	  when	  the	   8th	   subject	   was	   removed	   less	   SD	   was	   obtained	   and	   the	   result	   resembled	  more	   the	   results	   from	   other	   studies	   where	   dexmedetomidine	   has	   been	  administered	   extravascularly.	   The	   pharmacokinetic	   population	   results	   for	   IV	  dexmedetomidine	  were	  similar	   to	  previous	  studies	  on	  healthy	  subjects.	  Weight	  was	   used	   as	   a	   covariate,	   where	   it	   was	   modeled	   by	   allometrically	   scaling	   the	  parameters.	  From	  the	  results	  it	  is	  shown	  that	  the	  covariate	  improved	  the	  model´s	  goodness	  of	  fit.	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